Co-crystal forms of novobiocin analogs with proline
By forming co-crystals with proline, the amorphous solid problem of novologue 4 is solved, its purity and bioavailability are improved, and the inhibitory effect on Hsp90 is enhanced. It is suitable for the treatment of diabetic peripheral neuropathy and other neurodegenerative diseases.
Patent Information
- Application Number
- CN202410935084.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-02-07
- Filing Date
- 2019-02-01
- Publication Date
- 2024-11-05
AI Technical Summary
The synthesis of the existing neozoomycin analogue novologue 4 results in amorphous solids, and its bioavailability and purity are difficult to guarantee, and it cannot effectively inhibit heat shock proteins 90 (Hsp90) and Hsp70, affecting the neuroprotective effect.
By forming co-crystals with L-proline or D-proline, a variety of crystallization strategies and solvent systems are adopted to improve the purity and bioavailability of novologue 4a, and a variety of co-crystal forms such as B, D, and C type, G type, etc. to enhance their bioavailability.
It significantly improves the purity and bioavailability of novologue 4a, enhances its inhibitory effect on Hsp90, improves neuroprotective performance, and is suitable for the treatment of diabetic peripheral neuropathy and other neurodegenerative diseases.
Smart Images

Figure CN118894894A_ABST
Abstract
Description
[0001] This application is a divisional application of a Chinese patent application with an application date of February 1, 2019, application number 201980011980.6, and invention name “Co-crystal form of a neomycin analog and proline”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This patent application claims the benefit of priority to U.S. Application Serial No. 62 / 627,570, filed on February 7, 2018, the entire contents of which are incorporated herein by reference. Technical Field
[0004] The present invention relates to a co-crystal form of a novobiocin analog and proline. Background Art
[0005] Approximately 26 million Americans have type 1 or type 2 diabetes. Despite the use of insulin and oral antidiabetic medications to help maintain normal blood sugar, approximately 60% to 70% of these individuals will develop diabetic peripheral neuropathy (DPN). See Veves, A.; Backonja, M.; Malik, RA, Pain Med. 9 (2008) 660-674. It is reported that many small molecules based on the neomycin scaffold inhibit heat shock protein 90 (heat shock protein 90, Hsp90) and have important neuroprotective properties and can be used to reverse DPN symptoms in animal models. See BR Kusuma et al., J. Med. Chem. 55 (2012) 5797-5812; U.S. Patent No. 9,422,320.
[0006] One of the novomycin analogs ("novologues") of this type is N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4), which has been reported to exhibit high neuroprotective activity. Kusuma (2012). Some of the effects of novologue 4 have also been reported to depend on the presence of another heat shock protein, Hsp70, while other effects are independent of Hsp70. The exact role of Hsp70 in the mechanism of action of novologue 4 and related compounds has not been fully characterized. J. Ma et al., ACS Chem. Neurosci. 6(9) (2015) 1637-1648.
[0007] The synthesis of novologue 4 reportedly follows a procedure that leads to an amorphous solid, and its physicochemical characterization omits a definitive assignment of stereochemistry at the 2-position (Kusuma (2012); U.S. Patent No. 9,422,320), thereby allowing in principle the existence of two possible anomers 4a and 4b, as shown below:
[0008]
[0009] The published synthesis of 4 (also known as KU-596), while showing an HPLC purity of 95.6%, does not indicate anomeric purity of the amorphous solid, as evidenced by the fact that only the 2-position of noviose lacks a defined stereochemical assignment. (Kusuma (2012) Summary of the invention
[0010] The present disclosure is premised on the unexpected discovery that co-crystal forms of novologue 4a and L-proline or D-proline are achieved in high yield, purity and anomeric purity. In addition, the forms of the present invention exhibit significantly improved bioavailability relative to the known amorphous form 4.
[0011] Thus, one embodiment of the present disclosure is a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:2). The co-crystal is characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.76, 16.86, 19.00 and 21.05 ° 2θ ± 0.20 ° 2θ, as measured using a wavelength of The Cu-Kα radiation of 2.5 Å was determined on a diffractometer. This eutectic is referred to herein as "Form B".
[0012] Another embodiment is a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:2). The co-crystal is characterized by an X-ray powder diffraction pattern comprising the following peaks: 9.20, 16.19, 18.45 and 24.51 ° 2θ ± 0.2 ° 2θ, as measured using a wavelength of The Cu-Kα radiation of 2.5-1.5 N·m-1 was determined on a diffractometer. This eutectic is referred to herein as "Form D".
[0013] In addition, one embodiment is a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:1:1) in the form of an acetone solvate. The co-crystal is characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.64, 17.53, 18.91 and 21.33° 2θ ± 0.20° 2θ, as measured using a wavelength of The Cu-Kα radiation of 2.5 Å was determined on a diffractometer. This eutectic is referred to herein as "Form C".
[0014] In another embodiment, the present disclosure relates to a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline as a solvate of methyl ethyl ketone and pyrazine in a molar ratio of about 1:1.2:0.6:0.1, respectively. The co-crystal is characterized by an X-ray powder diffraction pattern comprising the following peaks: 10.42, 14.62, 19.28 and 21.14 °2θ±0.20 °2θ, as measured using a wavelength of The Cu-Kα radiation of 2.5-1.5 N·m was determined on a diffractometer. This eutectic is referred to herein as "Form G".
[0015] The present disclosure also provides a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and D-proline (1:1), which is characterized by an X-ray powder diffraction pattern comprising the following peaks: 11.77, 14.52, 19.54 and 21.23°2θ±0.20°2θ, as measured using a wavelength of Cu-K α1 The radiation is determined on a diffractometer.
[0016] The present disclosure also provides a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:1), which is characterized by an X-ray powder diffraction pattern comprising the following peaks: 8.52, 16.33, 19.50 and 21.22°2θ±0.20°2θ, as measured using a wavelength of Cu-Kα1 The radiation is determined on a diffractometer.
[0017] According to another embodiment, the present disclosure relates to a pharmaceutical composition comprising any one of the co-crystal forms described herein. The composition further comprises a pharmaceutically acceptable solid carrier. In some embodiments, the composition further comprises one or more additional co-crystal forms.
[0018] Another embodiment of the present disclosure is a method for inhibiting heat shock protein 90 (Hsp90) in a subject. The method comprises administering to the subject a therapeutically effective amount of a co-crystal described herein.
[0019] The present disclosure is also embodied in a method for treating or preventing a neurodegenerative disorder in a subject suffering from the neurodegenerative disorder. The method comprises administering to the subject a therapeutically effective amount of a co-crystal described herein. In some embodiments, the neurodegenerative disorder is diabetic peripheral neuropathy (DPN).
[0020] Alternatively, according to other embodiments, the present disclosure provides a method for preventing the occurrence of diabetic peripheral neuropathy or reducing the likelihood of developing diabetic peripheral neuropathy in a subject with type 1 or type 2 diabetes. The method comprises administering to the subject a therapeutically effective amount of a co-crystal described herein.
[0021] According to another embodiment, the present disclosure provides a method for preparing a B-type co-crystal. The method comprises the following steps: 1-6 A combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in a molar ratio of about 1:1 to about 1:2 in an alkyl alcohol is heated to a first temperature to obtain a solution. The solution is then cooled to a second temperature of no greater than about 30° C. to obtain a slurry of the co-crystal, and the slurry is then stirred at the second temperature for about 72 hours or less.
[0022] Another embodiment is a method of preparing a Form D co-crystal. The method comprises heating a combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in a molar ratio of about 1:1 in EtOH or acetonitrile to a first temperature, and then cooling the solution to a second temperature of no greater than about 30°C to obtain a suspension of the co-crystal. The suspension is then stirred at the second temperature for about 72 hours or less.
[0023] The present disclosure is embodied in another method for preparing Form C cocrystals. The method comprises (a) optionally refluxing equimolar amounts of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in EtOH to obtain a solution, and cooling the solution to a temperature of no more than about 30° C. to obtain a solid product. The product of step (a), or otherwise a combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in a molar ratio of about 1:1, is then stirred in acetone at a temperature of no greater than about 30°C for about 72 hours or less to provide a co-crystal.
[0024] According to another embodiment, the present disclosure provides a method for preparing a G-type co-crystal. The method includes combining N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a), L-proline and pyrazine in a mixed solvent of methyl ethyl ketone (MEK) and MeOH at a molar ratio of about 1:1:20, respectively, to obtain a solution, and then stirring the solution to obtain a co-crystal.
[0025] The present disclosure further provides a method for preparing a co-crystal of 4a / D-proline as described herein, the method comprising: 1-6 A combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and D-proline in a molar ratio of about 1:1 in an alkyl alcohol is heated to a first temperature to obtain a solution; the solution is cooled to a second temperature not higher than about 30° C., thereby obtaining a suspension of co-crystals.
[0026] In another embodiment, the present disclosure provides a method of increasing the concentration of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) relative to N-(2-(5-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4b) in a composition comprising 4a and 4b. The method comprises contacting the composition with proline in a solvent, and subjecting the composition, proline, and solvent to crystallization conditions, thereby producing a co-crystal of 4a and proline. The bulk co-crystal showed a higher concentration of 4a than the composition comprising 4a and 4b. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The X-ray powder diffraction (XRPD) pattern of Form B is shown.
[0028] Figure 2 It is a differential scanning calorimetry (DSC) curve of type B.
[0029] Figure 3 This is a type B thermogravimetric analysis (TGA) curve.
[0030] Figure 4 It is a type B dynamic vapor sorption (DVS) curve.
[0031] Figure 5 It is the infrared (IR) spectrum of type B.
[0032] Figure 6 This is the Raman spectrum of type B.
[0033] Figure 7 is the atomic displacement ellipsoid diagram of form B determined by single crystal X-ray crystallography.
[0034] Figure 8 is the calculated XRPD pattern of Form B determined based on the single crystal structure.
[0035] Fig. 9Shown is a comparison of the calculated XRPD pattern of Form B (bottom trace) and the experimental XRPD pattern of Form B (top trace).
[0036] Fig.10 The X-ray powder diffraction (XRPD) pattern of Form C is shown.
[0037] Fig.11 It is the thermogravimetric analysis (TGA) curve of type C.
[0038] Fig.12 is the atomic displacement ellipsoid diagram of form C determined by single crystal X-ray crystallography.
[0039] Fig.13 is the calculated XRPD pattern of Form C based on single crystal structure determination.
[0040] Fig.14 The X-ray powder diffraction (XRPD) pattern of Form D is shown.
[0041] Fig.15 DSC (bottom trace) and TGA (top trace) curves of Form D are shown.
[0042] Fig.16 It is the dynamic vapor sorption (DVS) curve of type D.
[0043] Fig.17 The X-ray powder diffraction (XRPD) pattern of Form G is shown.
[0044] Fig.18 Shown is the X-ray powder diffraction (XRPD) pattern of 4a / D-proline co-crystals.
[0045] Fig.19 Shown are the DSC (bottom trace) and TGA (top trace) curves of the 4a / D-proline co-crystal.
[0046] Fig. 20 is the dynamic vapor sorption (DVS) curve of 4a / D-proline co-crystal.
[0047] Fig.21 Shown are the mean plasma concentrations of 4a in mice after administration of a single oral dose of Material A (·) and amorphous 4a (○).
[0048] Fig. 22 Shown are the results of administration of a single oral dose of Material A (·) and Amorphous 4a (○) by oral gavage and Material A in loose-filled capsules. and the mean plasma concentrations of 4a in monkeys after administration of amorphous 4a(Δ).
[0049] Fig.23The X-ray powder diffraction (XRPD) pattern of 4a / L-proline co-crystal material A is shown.
[0050] Fig.24 DSC (bottom trace) and TGA (top trace) curves of 4a / L-proline co-crystal Material A are shown.
[0051] Fig.25 is the dynamic vapor sorption (DVS) curve of 4a / L-proline co-crystal material A. DETAILED DESCRIPTION
[0052] definition
[0053] Abbreviations, acronyms and terms used throughout this disclosure have the following meanings.
[0054]
[0055]
[0056]
[0057] introduce
[0058] As mentioned above, studies on novologue 4 highlighted the compound's superior potency in Hsp70-independent inhibition of Hsp90 (Kusuma (2012) and Ma (2015)). Studies have revealed potential drawbacks to the synthesis of this compound, including its tendency to result in a mixture of α-anomer 4a and β-anomer 4b and a low overall yield. In addition, although the reported column chromatography purification method for 4 is suitable for small-scale studies, even though the purity of the compound is about 95% (HPLC), this method is still impractical for producing large quantities of pharmaceutically pure α-anomer 4a for drug development.
[0059] Therefore, the inventors adopted various crystallization strategies to separate 4a. However, the inventors found that there was no condition that could separate 4a from 4b by crystallization.
[0060] The inventors performed a co-crystal screen of 28 co-formers on amorphous 4a and unexpectedly found that L-proline and D-proline selectively co-crystallized with the α-anomer 4a. In addition, the inventors found that L-proline and D-proline were the only co-formers tested that produced any crystalline material suitable for definitive characterization (see Example 3).
[0061] Co-crystal form
[0062] Contacting compound 4 with the coformers L-proline or D-proline unexpectedly results in the selective co-crystallization of 4a with either coformer (see Examples 2 and 10). In this manner, the co-crystals achieve a high enrichment of 4 in 4a relative to 4b, e.g., as determined by HPLC. Thus, in one embodiment, the selective co-crystalization of 4a with L-proline reduces the concentration of the β-anomer and facilitates the removal of trace impurities. Thus, forming 4a / L-proline co-crystals increases the purity (HPLC) of 4a from about 90% to at least 95%, 96%, 97%, or 98%. Subsequent recrystallization of 4a / L-proline co-crystals further increases the purity of 4a to at least 97%, 98%, or 99%.
[0063] Similarly, in other embodiments, the starting composition of 4a and 4b is co-crystallized with D-proline, for example, in approximately equimolar amounts of 4a / 4b and D-proline to obtain a 4a / D-proline co-crystal, wherein the purity (i.e., concentration) of 4a relative to the concentration of 4a in the starting composition as determined by HPLC is increased by at least 15%, 10%, 5%, or 3%. Thus, for example, the starting composition 4a / 4b comprises 4a at a concentration of about 93%, and after co-crystallization with D-proline, the resulting co-crystal comprises 4a at a concentration of about 98%. In some embodiments, the 4a / D-proline co-crystal comprises 4a at a final purity of at least 85%, 90%, 95%, 97%, 98%, or 99%.
[0064] In other embodiments, purification is performed by contacting an amount of the α-anomer 4a with D-proline (e.g., in equimolar amounts), thereby producing a 4a / D-proline co-crystal. The resulting concentration of 4a in the bulk co-crystal is, for example, at least 1%, 2%, 3%, 4%, or 5% (HPLC) higher than the concentration of 4a in the starting amount of 4a. Each of these embodiments contemplates the optional step of one or more recrystallizations to even further increase the purity of 4a in a given co-crystal.
[0065] Co-crystallization also produces multiple co-crystal forms as outlined above. The multiple forms are identified and differentiated by one or more analytical techniques including X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA).
[0066] Type B
[0067] Thus, one embodiment, denoted Form B, is a co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in a molar ratio of 1:2, respectively. The X-ray powder diffraction pattern comprises characteristic peaks at 14.76, 16.86, 19.00 and 21.05° 2θ ± 0.2° 2θ, as measured using a wavelength of In one embodiment, the X-ray powder diffraction pattern further comprises peaks at 12.14, 17.51, 18.89 and 19.41 ° 2θ ± 0.2 ° 2θ. According to yet another embodiment, Form B is also substantially characterized by its entire X-ray powder diffraction pattern (see Figure 1 ) to characterize.
[0068] The DSC curve of Form B is characteristic of the co-crystal in that it exhibits an exotherm at about 211°C. According to one embodiment, Form B is prepared by substantially Figure 2 The entire DSC thermogram is shown.
[0069] The present disclosure is also embodied in a method for preparing Form B (see Example 4). The method comprises: 1-6 A combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and D-proline in a molar ratio of about 1:1 to about 1:2 in a -alkyl alcohol is heated to obtain a solution. In some embodiments, 4a is present as pure 4a, while in other embodiments, 4a is present in combination with the β-anomer 4b, such as a combination resulting from a disclosed synthesis of 4 (Kusuma 2012, supra). For example, 4a is present at 95%, 96%, 97%, 98%, or 99% (w / w). The composition is heated to a first temperature of about 50°C to about 80°C. Exemplary C 1-6 -Alkyl alcohols include methanol, ethanol and n-propanol and isopropanol. In one embodiment, the alcohol is ethanol. According to one embodiment, a convenient first temperature is the boiling point of the alcohol at standard pressure. Thus, for example, when ethanol is the alcohol, the first temperature is the boiling point, i.e., about 78°C.
[0070] The method further comprises the step of cooling the solution of 4a and L-proline to a second temperature of no greater than about 30°C to obtain a slurry of the co-crystals. The slurry is stirred at the second temperature for about 72 hours or less. In one embodiment, the slurry is filtered to isolate Form B.
[0071] Type D
[0072] The present disclosure is also embodied as a co-crystal of 4a and L-proline in a 1:2 molar ratio, and is denoted Form D. Form D is characterized by an X-ray powder diffraction pattern comprising the following peaks: 9.20, 16.19, 18.45, and 24.51° 2θ ± 0.2° 2θ peaks, as measured using a wavelength of Another embodiment involves additional characteristic peaks occurring at 11.83, 17.16, 20.15 and 25.34° 2θ ± 0.2° 2θ. Form D also consists essentially of Fig.14 The X-ray powder diffraction pattern is shown.
[0073] The DSC curve of Form D is also characteristic of the co-crystal, characterized in that it exhibits an endotherm at about 212.2° C. with an onset temperature of about 211.2° C. According to one embodiment, Form D is prepared by substantially Fig.15 The entire DSC thermogram is shown.
[0074] Embodiments of the present disclosure also relate to methods for preparing Form D. The method comprises heating a combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in a molar ratio of about 1:1 in EtOH or acetonitrile to a first temperature. In some embodiments, 4a is present as pure 4a, while in other embodiments, 4a is present in combination with β-anomer 4b, such as a combination resulting from the disclosed synthesis of 4 (Kusuma 2012, supra). For example, 4a is present at 95%, 96%, 97%, 98% or 99% (w / w). The first temperature is a temperature selected in the range of about 70°C to about 85°C. For example, a suitable temperature may be achieved by reflux the composition, ie, at the boiling point of acetonitrile, about 82°C.
[0075] The method further comprises the steps of cooling the solution to a second temperature of no greater than about 30°C to obtain a suspension of the co-crystals, and then stirring the suspension at the second temperature for about 72 hours or less. According to one embodiment, the suspension is filtered to isolate Form D, for example.
[0076] Type C
[0077] The present disclosure also embodies an acetone solvate of a co-crystal of 4a and L-proline in a 1:1:1 molar ratio, and is designated Form C (see Example 6). The co-crystal is characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.64, 17.53, 18.91, and 21.33° 2θ ± 0.2° 2θ, as measured using a wavelength of More specifically, according to another embodiment, the X-ray powder diffraction pattern comprises additional peaks at 12.10, 15.14, 18.26 and 19.56° 2θ ± 0.2° 2θ. These peaks and additional peaks characteristic of Form C are substantially as follows: Fig.10 Its X-ray powder diffraction pattern is shown in the figure.
[0078] Form C is further characterized by reference to its TGA thermogram, which includes a weight loss step that is completed at about 150° C. to about 220° C. One embodiment depicts a TGA thermogram of Form C substantially as Fig.11 shown.
[0079] Form C is prepared by a method according to various embodiments of the present disclosure. Thus, in one embodiment, the method comprises refluxing equimolar amounts of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and L-proline in EtOH to obtain a solution, and then cooling the solution to a temperature of no greater than about 30° C. to obtain a solid product. The solid product is then stirred in acetone at a temperature of no greater than about 30° C. for about 72 hours or less to obtain Form C.
[0080] Alternatively, a combination of 4a and L-proline in a molar ratio of about 1:1 is stirred in acetone at a temperature no greater than about 30°C for about 72 hours or less to provide Form C. In any of these embodiments, 4a is present as pure 4a or in combination with the β-anomer 4b, such as produced by the disclosed synthesis of 4. In another embodiment, Form C is isolated, such as by filtration.
[0081] Type G
[0082] The present disclosure also relates to a co-crystal of 4a and L-proline that exists as a solvate of methyl ethyl ketone and pyrazine and is designated Form G (see Example 9). As described in the Examples, the XRPD index of Form G is consistent with a 1:1 molar ratio of 4a:L-proline, but the index is unable to distinguish between MEK and pyrazine molecules of comparable size, making a definite amount of solvent difficult to establish by this analytical technique. However, proton NMR analysis of Form G determined that the molar ratios of 4a, L-proline, MEK, and pyrazine were approximately 1:1.2:0.6:0.1, respectively. Thus, Form G is characterized by its XRPD diffraction pattern having characteristic peaks at 10.42, 14.62, 19.28, and 21.14° 2θ ± 0.2° 2θ, as measured using a wavelength of Another embodiment provides additional peaks at 11.85, 14.93, 17.40 and 19.28° 2θ ± 0.2° 2θ. Form G can also be obtained by substantially Fig.17 The complete XRPD diffraction pattern is shown.
[0083] According to another embodiment, XRPD analysis of Form G also establishes the unit cell parameters that characterize the co-crystal. Thus, the parameters are α=90°, β=108.56°, and γ=90°.
[0084] The present disclosure also relates to a method for preparing Form G. The method comprises combining N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a), L-proline, and pyrazine in a mixed solvent of methyl ethyl ketone (MEK) and MeOH in a molar ratio of about 1:1:20, respectively, to obtain a solution. In some embodiments, 4a is present as pure 4a, while in other embodiments, 4a is present in combination with β-anomer 4b, such as a combination resulting from the disclosed synthesis of 4 (Kusuma 2012, supra). For example, 4a is present at 95%, 96%, 97%, 98%, or 99% (w / w). Typically, the mixed solvent is embodied in an excess of MEK relative to MeOH. Thus, an exemplary ratio of MEK to MeOH is about 9:1 (v / v). The solution is then stirred to obtain Form G.
[0085] Material A
[0086] Another embodiment of the present disclosure is a co-crystal of 4a and L-proline in a molar ratio of 1:1, and is denoted as Material A. Material A is characterized by an X-ray powder diffraction pattern comprising the following peaks: 8.52, 16.33, 19.50, and 21.22° 2θ ± 0.20° 2θ, as measured using a wavelength of Cu-K α1 Another embodiment involves additional characteristic peaks occurring at 9.19, 13.22, 14.75 and 17.57° 2θ ± 0.2° 2θ. Material A is also prepared by substantially Fig.23 The X-ray powder diffraction pattern is shown.
[0087] According to another embodiment, XRPD analysis of Material A also establishes the unit cell parameters that characterize the co-crystal. Thus, the parameters are: α=90°, β=90°, and γ=90°.
[0088] The DSC curve of Material A is also characteristic of the co-crystal, characterized in that it exhibits an endotherm at about 145°C. According to one embodiment, Material A is prepared by substantially Fig.24 The entire DSC thermogram is shown.
[0089] Additionally, Material A is characterized by reference to its TGA thermogram, which includes a weight loss step that is completed at about 160° C. to about 230° C. One embodiment depicts a TGA thermogram of Material A substantially as Fig.24 shown.
[0090] 4a / D-proline cocrystal
[0091] In another embodiment, the present disclosure also provides a co-crystal of 4a and D-proline in a 1:1 molar ratio (see Example 11). The co-crystal is characterized by its XRPD diffraction pattern, which has characteristic peaks at 11.77, 14.52, 19.54 and 21.23° 2θ ± 0.20° 2θ, as measured using a wavelength of Cu-K α1 The radiation was determined on a diffractometer. Other characteristic peaks appear at 8.45, 13.18, 16.95 and 19.12° 2θ ± 0.2° 2θ. These peaks and additional peaks characteristic of the cocrystal are essentially as Fig.18 Its X-ray powder diffraction pattern is shown in the figure.
[0092] The DSC curve of the 4a / D-proline crystals is also characteristic of the co-crystals, characterized in that it exhibits an endotherm at about 130°C. According to one embodiment, the co-crystals are prepared by substantially Fig.19The entire DSC thermogram is shown.
[0093] The co-crystal is further characterized by reference to its TGA thermogram, which includes two weight loss steps ending at about 150 to 160° C. and about 230° C., respectively. One embodiment depicts a TGA thermogram of the co-crystal, substantially as Fig.19 shown.
[0094] The present disclosure also provides a method for preparing 4a / D-proline crystals. The method comprises the following steps: (a) 1-6 The invention relates to a method for preparing a co-crystal of the present invention. The method comprises heating a combination of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) and D-proline in a molar ratio of about 1:1 in a 4-alkyl alcohol to a first temperature to obtain a solution; and (b) cooling the solution to a second temperature no greater than about 30°C to obtain a suspension of co-crystals. In some embodiments, 4a is present as pure 4a, while in other embodiments, 4a is present in combination with the β-anomer 4b, such as a combination resulting from the disclosed synthesis of 4 (Kusuma 2012, supra). For example, 4a is present at 95%, 96%, 97%, 98% or 99% (w / w).
[0095] Purification methods
[0096] According to one embodiment, the unexpected discovery that 4a selectively co-crystallizes with L-proline and D-proline yields a method for purifying 4a from a large amount of 4. That is, co-crystallization of 4a with proline enriches the concentration of 4a relative to 4b in a bulk sample of the 4a / proline co-crystal. The method of increasing the concentration of 4a first considers a starting composition of 4a and 4b. The starting composition can be a bulk solid produced by a disclosed synthesis of 4 or by one of many alternative synthetic pathways known or reasonably contemplated by one skilled in the art of organic synthesis that can lead to 4. Alternatively, the starting composition can be a bulk solid of primarily 4a produced by other purification methods, such as column chromatography. The inventors unexpectedly discovered in this regard that 4a defied all attempts at crystallization; in fact, 4a was not observed to exist in crystalline form under any conditions. In any of these examples, the starting composition contains at least some amount of 4b, such as 0.5% to about 10% (w / w).
[0097] A molar excess of proline, e.g., one to about two equivalents, is combined with the starting composition in a solvent. In some embodiments, the proline is L-proline, and in other embodiments, the proline is D-proline. A mixture of L-proline and D-proline may be used. Any solvent capable of substantially dissolving the proline and the starting composition is suitable for this purpose. Exemplary solvents, e.g., any solvent described herein, include C1-C6-alkyl alcohols, e.g., methanol and ethanol. In some embodiments of the method, it is advantageous to promote dissolution by heating the starting composition, proline, and solvent mixture. A suitable temperature for this purpose is the reflux temperature of the solvent.
[0098] The combination of the starting composition, proline, and solvent is then subjected to crystallization conditions to achieve co-crystallization of 4a with proline. A variety of crystallization techniques are available herein, such as any of the techniques described herein. In an exemplary embodiment, the warm solution of the starting composition and proline is cooled to room temperature. External cooling measures can be used to cool the solution to below room temperature to promote co-crystallization. As an alternative or in combination, the solvent is slowly evaporated. Any of these means, alone or in combination, will disrupt the equilibrium of the solution, thereby leading to crystallization.
[0099] The resulting bulk co-crystals of 4a with proline are thus enriched in 4a relative to the concentration of 4a in the starting composition. The corresponding concentration of 4b is reduced. In addition, the method purifies 4a from other impurities. A convenient method for quantifying the concentration of 4a is by HPLC, although any analytical technique capable of resolving and quantifying the components present in a mixture is suitable for this purpose, including gas chromatography (GC) on a chiral stationary phase. Thus, for example, the concentration of 4a in the bulk co-crystal is about 3% to about 20%, or about 5% to about 15% (w / w) higher than in the starting composition. Alternatively, the increase in 4a in the bulk co-crystal is at least about 5%, about 10% or about 15% (w / w) relative to the concentration of 4a in the bulk starting composition. Thus, for example, the starting composition 4 comprises about 93% 4a and about 6% 4b as determined by HPLC (see Example 10(A)). After co-crystallization with L-proline as described in the method of the present invention, the amount of 4b in the resulting bulk co-crystal is reduced to about 2.5%. In any of these embodiments, subsequent recrystallization of the 4a / proline co-crystals can further reduce the amount of 4b in the bulk material.
[0100] The present disclosure relates to diagrams such as XRPD patterns in terms of their characteristic peaks. For a given co-crystal form, the combination of these peaks is unique within the uncertainty introduced by the individual instrument and experimental conditions. Thus, for example, each XRPD peak is disclosed in 2θ angles with an acceptable uncertainty of ±0.2° 2θ, so that it is understood that the variance of the characteristic peaks within this uncertainty in no way impairs the identity of the co-crystal form having the corresponding combination of its characteristic peaks.
[0101] Pharmaceutical composition
[0102] The present disclosure also contemplates as another embodiment a pharmaceutical composition comprising a co-crystal as described herein. As explained in the Examples, the co-crystals of the present invention unexpectedly exhibit much greater bioavailability than 4a alone, i.e., as an amorphous solid. Thus, pharmaceutical compositions can be formulated to contain lower concentrations of co-crystals relative to formulations containing amorphous 4a to achieve the same therapeutic effect. With this benefit of the co-crystals of the present invention, a therapeutically effective amount of the co-crystal in a pharmaceutical composition provides a dosage of about 0.1 mg to about 1000 mg, adjusted as needed based on the subject's body weight. Typical dosages can vary from about 0.01 mg / kg to about 100 mg / kg per day.
[0103] According to the recognized practice of pharmaceutical compounding, the pharmaceutical composition also contains one or more pharmaceutically acceptable excipients, diluents, adjuvants, stabilizers, emulsifiers, preservatives, colorants, buffers or flavoring agents, which together constitute a pharmaceutically acceptable carrier. Typically, the pharmaceutical composition is prepared using conventional materials and techniques such as mixing, blending, etc. In principle, the pharmaceutically acceptable carrier can be a liquid as long as the co-crystal maintains compositional stability and structural stability, for example by not dissolving in the carrier. However, typically, the pharmaceutically acceptable carrier and therefore the entire composition is a solid.
[0104] According to some embodiments, the pharmaceutical composition further comprises one or more additional co-crystals as disclosed herein. For example, the composition comprises two forms, three forms, or four forms. An exemplary composition comprises Form B and Form D. Binary compositions, i.e., those comprising only two forms, provide the forms in various weight ratios of about 0.05:1 to about 1:0.05. Intermediate ratios and ranges are also contemplated, such as 0.2:1 to about 1:0.2, and 0.5:1 to about 1:0.5.
[0105] For tablet compositions, the co-crystals of the invention are mixed with non-toxic pharmaceutically acceptable excipients for the manufacture of tablets. Examples of such excipients include, but are not limited to: inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin or acacia; and lubricants such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or coated by known coating techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained therapeutic effect over a desired period of time. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be used.
[0106] Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil. These formulations, as well as all other liquid formulations described herein, are subject to the limitations described above to maintain the composition and structural integrity of the solid co-crystal.
[0107] According to the following embodiments, the pharmaceutical composition is present as a suspension. The embodiments relate to a "stable suspension", meaning that a given co-crystal or combination of co-crystals retains its characteristics, e.g., XRPD peaks, even when in contact with other components of the suspension, i.e., by not dissolving in the liquid excipient of the suspension, not converting into another co-crystal or amorphous form, or both.
[0108] For aqueous suspensions, the co-crystals of the invention are mixed with excipients suitable for maintaining a stable suspension. Examples of such excipients include, but are not limited to, sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, and gum arabic.
[0109] Oral suspensions may also include dispersants or wetting agents, such as naturally occurring phosphatides, such as lecithin, or condensation products of alkylene oxide and fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide and long-chain aliphatic alcohols, such as 17-carbon ethyleneoxy hexadecanol, or condensation products of ethylene oxide and the partial ester derived from fatty acids and hexitol, such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide and the partial ester derived from fatty acids and hexitol anhydrides, such as polyethylene sorbitan monooleate. Aqueous suspensions may also include one or more preservatives (such as ethyl p-hydroxybenzoate or n-propyl p-hydroxybenzoate), one or more coloring agents, one or more flavoring agents, and one or more sweeteners (such as sucrose or saccharin).
[0110] Oily suspensions can be formulated by suspending the active ingredient in a vegetable oil (eg, arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (eg, liquid paraffin). Oily suspensions may contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol.
[0111] Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
[0112] Dispersible powders and granules suitable for preparing aqueous suspensions by adding water can provide the active ingredient mixed with a dispersant or wetting agent, a suspending agent and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are exemplified by those already mentioned above. Other excipients, such as sweeteners, flavoring agents and coloring agents, may also be present.
[0113] The pharmaceutical composition of the present invention can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifiers can be naturally occurring gums, such as gum arabic or tragacanth; naturally occurring phospholipids, such as soybeans, lecithin; and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate and condensation products of the partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion can also contain sweeteners and flavoring agents.
[0114] Syrups and elixirs can be formulated with sweeteners such as glycerol, propylene glycol, sorbitol or sucrose. Such preparations may also contain demulcents, preservatives, and flavoring and coloring agents. Pharmaceutical compositions may be in the form of sterile injections, aqueous suspensions or oily suspensions. The suspensions may be formulated using suitable dispersants or wetting agents and suspending agents as mentioned above according to known techniques. Sterile injection preparations may also be sterile injectable solutions or suspensions in nontoxic, parent-acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable carriers and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are typically used as solvents or suspension media. For this purpose, any mild fixed oil may be used, including synthetic monoglycerides or diglycerides. In addition, it has been found that fatty acids such as oleic acid may be used in the preparation of injections.
[0115] The co-crystals of the invention may also be administered in the form of suppositories for rectal administration of the co-crystals. These compositions may be prepared by mixing the co-crystals with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the co-crystals. Examples of such materials are cocoa butter and polyethylene glycols.
[0116] Compositions for parenteral administration are administered in a sterile medium. Depending on the vehicle used and the concentration of the cocrystal in the formulation, the parenteral formulation may be a suspension of the cocrystal, provided that the particle size distribution of the cocrystal is suitable for this mode of administration. Excipients, such as local anesthetics, preservatives and buffers may also be added to the parenteral composition.
[0117] How to use
[0118] As demonstrated by the accompanying examples, one unexpected advantage conferred by the co-crystals of the present invention is the ability to manufacture large quantities of 4a in very high diastereomeric and chemical purity. This is particularly important for developing 4a that complies with Good Manufacturing Practice (GMP) regulations, such as those promulgated by the U.S. Food and Drug Administration. In contrast, the synthesis of amorphous 4a requires subsequent and laborious separation techniques, such as chromatography - as described above, all crystallization attempts were unsuccessful - which still cannot effectively isolate 4a in high chemical and diastereomeric purity for GMP purposes. For these reasons, the co-crystals of the present invention and methods for their preparation provide large quantities of 4a that can be used in clinical trials and commercialization efforts.
[0119] Another advantage of the co-crystals of the present invention is that 4a from the co-crystals has an unexpectedly high bioavailability compared to amorphous 4a. More specifically, administration of the co-crystals in vivo can increase the bioavailability of 4a by about 1.5 to 2 times compared to the same dose of amorphous 4a (see Examples 12 and 13). This feature of the co-crystals of the present invention is even more unexpected, given that it is generally observed that amorphous forms of drugs are significantly more soluble and therefore have higher bioavailability than their crystalline counterparts, and the present invention is actually the opposite. See, BC Hancock et al., Pharm. Res. 17 (4) (2000) 397–-404; BC Hancock et al., J. Pharm. Sci. 86 (1) (1997) 1-–12.
[0120] In view of these advantages, the present invention also relates to the use of any co-crystal form, including pharmaceutical compositions thereof, for treating or preventing a neurodegenerative disorder in a subject suffering from the neurodegenerative disorder. Non-limiting examples of such neurodegenerative disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, spinal muscular atrophy, spinocerebellar ataxia and ataxic forms, and demyelinating neurological disorders including motor neuron disease. In addition, the co-crystal form and pharmaceutical compositions thereof can be used to treat diabetic neuropathy (including both painful and sensitive forms thereof) and other forms of neuropathy, including non-diabetic neuropathic pain.
[0121] Based on the reported use of compound 4a in neurons to improve impaired mitochondrial function and reduce the expression of inflammatory markers in diabetic neurons (Ma (2015)), the co-crystal form and its pharmaceutical composition may also be used to treat neurological disorders involving mitochondrial dysfunction, oxidative stress or inflammation. Because diabetic tissues are subject to significant oxidative stress, these results suggest that the co-crystal form of the present invention and its pharmaceutical composition may be used to treat other neurological disorders involving oxidative stress and chronic inflammation, including epilepsy, multiple sclerosis, spinal cord injury and psychiatric disorders, including schizophrenia, depression, bipolar disorder, autism and related disorders, and post-traumatic stress disorder. The compositions and co-crystal forms may be used in combination with other treatments, particularly treatments that reduce oxidative stress, inflammation and mitochondrial dysfunction by other mechanisms.
[0122] As used herein, the term "neurodegenerative disorder" refers to a disorder in which there is a progressive loss of neurons in the peripheral nervous system or in the central nervous system. Thus, in one embodiment, the present disclosure provides a method for inhibiting Hsp90 in a subject by inhibiting the progressive degeneration of neurons leading to cell death, e.g., during or in accordance with the treatment of a neurodegenerative disorder.
[0123] The methods described herein comprise administering to a subject a therapeutically effective amount of a co-crystal of the invention. Within the above dosage guidelines, a "therapeutically effective amount" is an amount of a co-crystal that wholly or partially inhibits the progression of a disorder or at least partially alleviates one or more symptoms of a disorder. A therapeutically effective amount may also be a prophylactically effective amount. The therapeutically effective amount will depend on the size and sex of the patient, the disorder to be treated, the severity of the disorder, and the outcome sought. For a given patient and disorder, a therapeutically effective amount can be determined by methods known to those skilled in the art.
[0124] In various embodiments, the methods entail preventing a neurological disorder. The term "prevention" as used herein means that it is useful when the co-crystals of the invention are administered to a subject who, at the time of administration, has not been diagnosed as possibly having the disorder but is generally expected to develop the disorder or is at an increased risk of developing the disorder. The co-crystals of the invention slow the onset of the disorder symptoms, delay the onset of the disorder, or completely prevent the subject from developing the disorder. Prevention also contemplates administering the co-crystals to a subject who is susceptible to the disorder due to age, family history, genetic or chromosomal abnormalities, and / or due to the presence of one or more biomarkers for the disorder.
[0125] In other embodiments, the methods of the invention entail "treatment", which means the use of a co-crystal in a subject with at least a preliminary diagnosis of a disorder. Thus, the co-crystals of the invention delay or slow the progression of the disorder. Additionally, the term "treatment" includes at least amelioration of symptoms associated with the disorder, wherein amelioration broadly refers to at least a reduction in the magnitude of a parameter (e.g., symptom) associated with the disease being treated. Thus, "treatment" also includes situations in which the disorder or at least a symptom associated therewith is completely inhibited, e.g., prevented from occurring or brought to a halt, e.g., terminated, such that the subject no longer suffers from the disorder or at least no longer suffers from symptoms that characterize the disorder.
[0126] In one embodiment, the neurodegenerative disorder is sensory neuron glycotoxicity caused by hyperglycemia, such as that associated with a diabetic condition. For example, the subject suffers from type 1 or type 2 diabetes. More specifically, according to one embodiment, the neurodegenerative disorder is diabetic peripheral neuropathy. Thus, in one embodiment, the methods of the present invention include preventing the occurrence of diabetic peripheral neuropathy or reducing the likelihood of the occurrence of diabetic peripheral neuropathy in a subject suffering from type 1 or type 2 diabetes.
[0127] In the context of the methods and uses of the invention, a "subject" to be treated with the co-crystals of the invention is an animal, and preferably a mammal, such as a dog, cat, mouse, monkey, rat, rabbit, horse, cow, guinea pig, sheep. In one embodiment, the subject is a human.
[0128] Example
[0129] The following non-limiting examples are provided to illustrate other embodiments of the present disclosure.
[0130] For example, amorphous 4a was obtained at about 95% purity (HPLC) according to published procedures (Kusuma (2012) and US Pat. No. 9,422,320).
[0131] I. General Crystallization Experimental Methods
[0132] Collision Precipitation (CP): Solutions of 4a were prepared in various solvents or solvent systems with various coformers at given molar ratios and under stirring. Aliquots of various antisolvents were dispensed under stirring until precipitation occurred. The mixture was stirred for the specified time. Where specified, additional crystallization techniques were employed.
[0133] Fast Evaporation (FE): Solutions of 4a were prepared in various solvents with various coformers at given molar ratios and under stirring. Unless otherwise stated, each solution was allowed to evaporate from an open vial under ambient conditions. Solutions were allowed to evaporate to dryness unless specified as partial evaporation (solids present with a small amount of solvent remaining), in which case the solids were isolated by the specified method or an additional crystallization technique was used as specified.
[0134] Manual grinding: Weighed amounts of 4a and various coformers were transferred to an agate mortar. A small amount of the given solvent was added to the solids and the mixture was manually ground for the given time using an agate pestle.
[0135] Grinding: Weighed amounts of 4a and the given coformer were transferred to an agate grinding container. A small amount of the given solvent and agate grinding balls were added to the container, which was then connected to a Retsch mill. The mixture was milled for 30 s. -1 Grinding is continued for a specified time. Solids are scraped from the tank walls between cycles.
[0136] Reactive Crystallization (RC): Mixtures of 4a with various coformers were prepared in a given solvent by adding a solid of one component to a solution of the second component. The solution was stirred for an extended time while enough solids were added so that the solution contained varying concentrations of each component (the molar concentration of one component relative to the other typically differed by a factor of 10 to 20). If specified, if no precipitation occurred, additional solids of the more concentrated component were added and the mixture was stirred again for an extended time. Any precipitated solids were isolated and analyzed.
[0137] Slow Cooling (SC): Concentrated solutions of 4a were prepared in various solvent systems with various coformers at given molar ratios at elevated temperature and stirring. Each vial was capped and left on a hot plate, which was then turned off to allow the sample to slowly cool to ambient temperature. If no solids were present after cooling to ambient temperature, the sample was placed in a refrigerator (approximately 2 to 8°C) and / or freezer (approximately -10 to -25°C) for further cooling. If no solids were present, other crystallization techniques were used as specified.
[0138] Slow Evaporation (SE): Solutions of 4a were prepared in various solvent systems with various coformers at given molar ratios. Each solution was evaporated at ambient conditions in a vial covered with aluminum foil perforated with small holes. Unless specified as a partial slow evaporation (wherein a portion of the solvent evaporated), the solution was evaporated to dryness. The resulting solid was isolated by the specified technique, or an alternative crystallization technique was used where specified.
[0139] Slurry experiments: Suspensions of 4a with various coformers at the stated molar ratios were prepared by adding enough solid to a given solvent system at ambient conditions such that insoluble solids were present. The mixture was then stirred (typically by stirring) in a sealed vial under the stated conditions for an extended period of time. The solids were collected by the stated techniques, or alternative crystallization techniques were employed where specified.
[0140] Vapor Diffusion (VD): Concentrated solutions of a given starting material (a given form of 4a / L-proline or a specified stoichiometric mixture of 4a and L-proline) were prepared in a variety of solvents. In some cases, the solutions were filtered through a 0.2-μm nylon filter. Each solution was dispensed into a vial, which was then placed into a larger vial containing a given antisolvent. Where specified, seeds of a given 4a / L proline form were added to the solution. The vials were left uncovered and the larger vials were capped to allow vapor diffusion to occur. Where specified, additional crystallization techniques were attempted.
[0141] Vacuum Filtration: Collect the solids by vacuum filtration onto a paper or nylon filter and air dry briefly on the filter under reduced pressure before transferring to a vial.
[0142] Interconverted Slurries: Solutions of a given starting material (a given 4a / L-proline form or a specified stoichiometric mixture of 4a and L-proline) were prepared by adding the solids to a given solvent system at a specified temperature. If a saturated solution was specified, the suspension was stirred at ambient temperature for an extended time to ensure saturation of the liquid phase. Seed crystals of each given 4a / L-proline form of interest were added to the prepared solution (or to the liquid phase filtered from the saturated solution) such that undissolved solids were present. Each mixture was then stirred (usually by stirring) in a sealed vial at a specified temperature for a given time. The solids were isolated by vacuum filtration and analyzed.
[0143] II. X-ray powder diffraction (XRPD) peak identification
[0144] Throughout this disclosure are X-ray diffraction patterns and tables with peak listings. Peaks within a range of up to about 30° 2θ were selected. Each peak was rounded to the nearest 0.01° 2θ using a rounding algorithm. The peaks were analyzed using proprietary software (TRIADS TM The positions of the peaks along the x-axis (°2θ) in both the graph and the table were determined using the HPLC-MS / MS software (v2.0) and rounded to two significant figures after the decimal point. The HPLC-MS / MS software was used according to the recommendations outlined in the USP discussion of X-ray powder diffraction variability (United States Pharmacopeia, USP 38-NF 33 to S2, <941> 12 / 1 / 2015), limiting the peak position variability to within ±0.2° 2θ. The accuracy and precision associated with any specific measurement disclosed herein has not been determined. In addition, third-party measurements of independently prepared samples on different instruments may result in variability greater than ±0.2° 2θ. The wavelength used to calculate the d spacing is Cu-K α1 Wavelength (Holzer, G.; Fritsch, M.; Deutsch, M.; Hartwig, J.; Forster, E. Phys. Rev. 1997, A56(6), 4554-4568). The variability associated with the d-spacing estimates was calculated at each d-spacing according to USP recommendations and is provided in the corresponding data tables.
[0145] According to USP guidelines, variable hydrate and solvate peak variances may be greater than 0.2° 2θ, so a peak variance of 0.2° 2θ is not applicable for these materials.
[0146] For samples with only one XRPD pattern and no other means to evaluate whether the sample provides a good approximation of the powder average, the peak table contains data identified only as "Prominent Peaks". These peaks are a subset of the entire observed peak list. Prominent peaks are selected from the observed peaks by identifying non-overlapping low-angle peaks, preferably with strong intensity.
[0147] In the case where multiple diffraction patterns are available, particle statistics (PS) and / or preferred orientation (PO) can be evaluated. The reproducibility between the XRPD patterns of multiple samples analyzed on a single diffractometer shows that particle statistics are sufficient. The consistency of the relative intensity between the XRPD patterns from multiple diffractometers indicates good orientation statistics. Alternatively, the observed XRPD pattern can be compared with the calculated XRPD pattern based on the single crystal structure (if available). The two-dimensional scattering pattern using a surface detector can also be used to evaluate PS / PO. If it is determined that the effects of both PS and PO are negligible, the XRPD pattern represents the average powder intensity of the sample, and the prominent peak can be identified as a "representative peak". Generally speaking, the more data collected to determine the representative peak, the more confident the classification of these peaks is.
[0148] "Characteristic peaks" are a subset of representative peaks to the extent they are present and are used to distinguish one crystalline polymorph from another (a polymorph is a crystalline form having the same chemical composition). Characteristic peaks are determined by evaluating the presence of representative peaks, if any, in one crystalline polymorph of a compound relative to all other known crystalline polymorphs of the compound within ±0.2° 2θ. Not all crystalline polymorphs of a compound must have at least one characteristic peak.
[0149] Device Technology
[0150] Differential Scanning Calorimetry (DSC): DSC was performed using a TA Instruments Q2000 differential scanning calorimeter. Temperature calibration was performed using NIST traceable indium metal. The sample was placed in an aluminum Tzero curled DSC pan, the lid was closed, and the weight was accurately recorded. A weighed aluminum pan configured as a sample pan was placed on the reference side of the unit cell.
[0151] Dynamic Vapor Sorption (DVS): Dynamic vapor sorption data were collected on a VTI SGA-100 vapor sorption analyzer. NaCl and polyvinypyrrolidone (PVP) were used as calibration standards. The samples were not dried prior to analysis. Adsorption and desorption data were collected over a range of 5% to 95% RH in 10% RH increments under a nitrogen purge. The equilibrium standard used for the analysis had a weight change of less than 0.0100% in 5 minutes, with a maximum equilibrium time of 3 hours. The data were not corrected for the initial moisture content of the samples.
[0152] EasyMax TM Reactor: Mettler Toledo EasyMax with Julabo F26 cooler / circulator TM Crystallization experiments were performed at 102. Crystallization was performed in 20 mL glass tubes (capped) under magnetic stirring. The temperature was controlled using the jacket temperature (Tj) setting.
[0153] Elemental Analysis: Elemental analyses were performed by Galbraith Laboratories, Knoxville, TN.
[0154] Infrared Spectroscopy (IR): IR spectra were acquired on a Nicolet 6700 Fourier transform infrared (FT-IR) spectrophotometer (Thermo Nicolet) equipped with an Ever-Glo mid / IR external light source, a potassium bromide (KBr) beam splitter, and a deuterated triglycine sulfate (DTGS) detector. Wavelength verification was performed using NIST SRM 1921b (polystyrene). An attenuated total reflectance (ATR) accessory (Thunderdome TM , Thermo Spectra-Tech) and germanium (Ge) crystals were used for data acquisition. Each spectrum represents a 4 cm -1 Spectral resolution was obtained from 256 co-added scans collected. A background data set was acquired with a clean Ge crystal. The Log 1 / R (R = reflectivity) spectrum was obtained by taking the ratio of these two data sets to each other.
[0155] Raman Spectra: Raman spectra were acquired on a FT-Raman module connected to a Nexus 670 FT-IR spectrophotometer (Thermo Nicolet) equipped with an indium gallium arsenide (InGaAs) detector. Wavelength verification was performed using sulfur and cyclohexane. Each sample was prepared for analysis by placing the sample in a particle holder. About 0.514 W of Nd:YVO4 laser power (1064 nm excitation wavelength) was used to irradiate the sample. Each spectrum represents a 4 cm -1 Spectral resolution collected from 256 co-added scans.
[0156] Single Crystal X-Ray Diffraction (SCXRD): The single crystal structures of 4a / L-proline Form B and Form C were determined at the Crystallography Laboratory at Purdue University.
[0157] Thermogravimetry (TGA): TG analysis was performed using a TA Instruments 2050 or Discovery thermogravimetric analyzer. Nickel and Alumel TM Temperature calibration was performed. Each sample was placed in an aluminum or platinum pan and inserted into a TG furnace. The furnace was heated from ambient temperature to 350°C at a heating rate of 10°C / min under a nitrogen purge.
[0158] Optical Microscopy: Samples were observed under a Wolfe optical microscope with crossed polarizers at 2× or 4× objectives, or under a Leica stereomicroscope with a first-order red compensator with crossed polarizers at 0.8× to 10× objectives.
[0159] Solution 1 H NMR spectroscopy: solution 1 H NMR spectra were obtained from Spectral Data Services of Champaign, IL, at 25 °C using Varian UNITY Acquired by INOVA-400 spectrometer. The samples were dissolved in DMSO-d6. The residual peak from the incompletely deuterated DMSO is at about 2.5 ppm, and the relatively broad peak at about 3.3 ppm is due to water.
[0160] X-Ray Powder Diffraction (XRPD)
[0161] PANalytical X'PERT Pro MPD Diffractometer – Transmission Geometry (most samples): XRPD patterns were collected with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu radiation produced using a long, finely focused light source. An elliptical graded multilayer mirror was used to focus the Cu Kα X-rays through the sample and to the detector. Prior to analysis, a silicon sample (NIST SRM 640e) was analyzed to verify that the position of the observed Si 111 peak was consistent with the NIST certified position. A sample of the sample was sandwiched between 3 μm thick films and analyzed in transmission geometry. A beam blocker, a short anti-scatter extension, and an anti-scatter edge were used to minimize the background generated by air. Soller slits for the incident and diffracted beams were used to minimize the broadening of the axial divergence. Diffraction patterns were collected using a scanning position sensitive detector (X'Celerator) positioned 240 mm from the sample and Data Collector software v.2.2b.
[0162] PANalytical X'PERT Pro MPD diffractometer - reflection geometry (limited sample): XRPD patterns were collected using a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu Kα radiation, which was generated using a long and fine focused source and a nickel filter. The diffractometer was configured using a symmetrical Bragg-Brentano geometry. Prior to analysis, a silicon sample (NIST SRM 640e) was analyzed to verify that the position of the observed Si 111 peak was consistent with the position certified by NIST. The sample was prepared as a thin circular layer centered on a silicon zero-background substrate. An antiscatter slit (SS) was used to minimize the background generated by air. Soller slits for the incident beam and the diffracted beam were used to minimize the broadening of the axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) positioned 240 mm from the sample and data collector software v.2.2b.
[0163] HPLC procedure
[0164] The table below shows the parameters and conditions for the HPLC measurements described herein. The reported HPLC purities for 4a and 4b do not take into account the peak for proline.
[0165]
[0166]
[0167] Example 1: Synthesis of 4a / L-proline co-crystal (Material A)
[0168]
[0169] Compound 4a was obtained by chromatography (HPLC: 4a, 96.4% and 4b, 1.2%, 500 mg) and mixed with L-proline (128 mg, 1 eq) in EtOH (4 mL). The mixture was heated to reflux for 15 min. The hot solution was filtered through a cotton plug. The resulting clear filtrate was slowly cooled and kept at room temperature for 16 h. The precipitated solid was collected by filtration and dried in air at room temperature to give 4a / L-proline co-crystals, which were designated as Material A (456 mg, 73% yield) as white solids. MP 203-205 °C. 1 H NMR showed that the ratio of 4a to L-proline was 1:1.1.
[0170] Material A is a 1:1 4a / L proline cocrystal, and it is probably an isostructural solvate. Material A contains less L-proline component based on the XRPD pattern ( Fig.23 ), which components have been successfully indexed (Table A1). For samples consisting primarily or solely of a single crystalline phase, XRPD indexing was generally successful. However, upon realizing that minor peaks / shoulder peaks at 8.7°, 15.0°, and 18.0° 2θ in the XRPD pattern were inconsistent with the indexing solution and could be attributed to L-proline, an indexing solution was obtained for this mixture. Selected unit cell parameters obtained from the indexing solution are shown in Table A2.
[0171] Table A1: Peaks observed for 4a / L-proline Material A
[0172]
[0173]
[0174] Table A2: Unit cell parameters of 4a / L proline material A
[0175]
[0176] The unit cell volume is large enough to accommodate the solvated 1:1 4a / L-proline co-crystals. The free volume (or unit cell volume remaining after the co-crystals are occupied) can be capable of accommodating water and / or any solvent from which Material A is generated, including EtOH, IPA, and THF.
[0177] Material A as described above was further characterized by DSC, TGA and DVS. The superposition of the DSC and TGA thermograms of this material is shown in Fig.24 The TGA thermogram shows two distinct weight loss steps, the first occurring between about 100°C and 160°C (7% by weight) and the second occurring between 160°C and 230°C (21% by weight). A broad endothermic peak was observed by DSC with a peak maximum at 145°C, which corresponds to the first TGA weight loss step. The relatively high temperatures at which these events occur and the stepwise nature of the weight loss may indicate a loss of bound solvent / water. The superimposed endothermic events at about 170°C to about 240°C by DSC correspond to the second weight loss step in the TGA thermogram, possibly corresponding to simultaneous melting of the co-crystal and volatilization of the L-proline component. The sharp drop above about 250°C in the TGA thermogram may correspond to decomposition.
[0178] Fig.25The DVS isotherm of Material A as described above is shown in . Because the material is characterized as a mixture with unreacted L-proline, it is unclear what effect, if any, excess L-proline may have on the vapor sorption behavior. The material exhibits significant hygroscopicity at or above 85% RH, absorbing approximately 6% by weight of vapor between 85% and 95 RH. The vapor sorption kinetic equilibrium timed out at 85% to 95% RH, indicating that the co-crystal could potentially absorb more water than measured if longer equilibrium times were allowed. A relatively steady weight loss was noted between 95% and 5% RH after desorption. The weight loss after desorption (approximately 8% by weight) was significantly higher than the weight loss obtained during adsorption, indicating that the material may have been solvated / hydrated at the beginning of the analysis. Analysis of the post-DVS material by XRPD showed a decrease in crystallinity, although the solid form remained intact. Due to the disorder in the XRPD pattern, the presence or absence of excess L-proline in the post-DVS sample could not be confirmed.
[0179] Example 2: Purification of 4a by co-crystallization with L-proline
[0180] 500 mg of a mixture consisting of compounds 4a and 4b (HPLC: 4a 92.0% and 4b 7.1%) and L-proline (128 mg, 1 eq.) in ethanol (4 mL) was refluxed for 15 min. The mixture was seeded with the co-crystals obtained in Example 1, and the mixture was allowed to cool and then kept at room temperature for 18 h. The white solid was filtered off, while the remaining solid was removed from the reaction flask together with the mother liquor. The amount of 4a / L-proline co-crystals collected (measured by 1 1:1 ratio as determined by H-NMR, 497 mg, 79% yield) consisted of 98.0% 4a and 1.49% 4b (by HPLC analysis).
[0181] Example 3: Co-crystal screening
[0182] Amorphous 4a was used with 26 coformers other than L-proline and D-proline in approximately 50 cocrystal screening experiments, as shown in Table 1 below. A variety of crystallization techniques suitable for cocrystal formation were used, including solvent-assisted grinding and manual grinding, cooling, evaporation, slurry, disintegration precipitation, and reactive crystallization, in which a solution containing a high molar excess of one component is combined with another component to promote a reaction equilibrium that favors cocrystal formation. A variety of coformers with functional groups capable of hydrogen bonding were used, including carboxylic acids, amino acids, sugars, amides, amines, and many functional aromatic compounds. However, 4a did not form any confirmed cocrystals with these common coformers under the various conditions and coformers studied in this screen.
[0183] Table 1
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196] a ,b Seeds of different batches of uncharacterized crystalline material containing 4a and pyroglutamic acid.
[0197] Example 4: Preparation and Characterization of 4a / L-Proline Form B
[0198] Equimolar amounts of amorphous 4a and L-proline (1:1) were mixed in methanol and heated to about 68°C. The resulting solution was allowed to slowly cool to room temperature, at which point a white suspension formed. The suspension was then stirred at room temperature for three days before Form B was collected as a white solid by filtration and dried.
[0199] Alternatively, amorphous 4a and L-proline were combined in a molar ratio of 1:2 in ethanol and heated to about 82°C to produce a white suspension. The suspension was maintained at 82°C for about 5 minutes, allowed to slowly cool to room temperature, and then stirred at room temperature for three days. Form B was collected as a white solid by filtration and dried.
[0200] Form B is an anhydrous 1:2 4a / L-proline cocrystal. Form B was characterized by XRPD (with index), DSC, TGA, DVS, Raman spectroscopy, IR spectroscopy, proton NMR, HPLC, and elemental analysis.
[0201] The XRPD pattern of Form B was successfully indexed (Table 2) and showed that Form B consisted primarily or exclusively of a single crystalline phase ( Figure 1 ). The unit cell volume obtained from the index solution is consistent with the anhydrous 1:2 4a / L-proline co-crystal. Table 3 below shows the unit cell parameters.
[0202] Table 2: Peaks observed for 4a / L-proline Form B
[0203]
[0204] Table 3: Unit cell parameters of 4a / L-proline form B
[0205]
[0206] A Form B sample isolated from the MeOH slurry was characterized by proton NMR and HPLC. The proton NMR data indicated a 1:2 4a / L-proline stoichiometry with no residual solvent detected. The purity of 4a in the sample was 99.7% as determined by HPLC.
[0207] Respectively Figure 2 and Figure 3 DSC and TGA thermograms of Form B are shown in . Since each technique analyzes different samples, the data are plotted separately. The sample analyzed by TGA was isolated from a MeOH slurry, while the DSC sample was obtained from a co-crystal formation experiment performed in MeOH. Little weight loss was observed between ambient temperature and 190°C by TGA, which is consistent with an anhydrous / non-solvated material. The DSC is also consistent with this, showing no significant thermal events until the onset of an endothermic event at 208°C, along with a superimposed strong exothermic event. Notably, after this analysis was performed, the sample was observed to bubble out of the pan, possibly due to the magnitude of the exotherm. These events may correspond to melting / dissociation of the co-crystal. Similarly, the sharp drop above 190°C in the TGA thermogram may be attributed to the volatilization of a portion of the L-proline component in the co-crystal, which may then decompose.
[0208] To further confirm the co-crystal stoichiometry, Form B was analyzed by elemental analysis of C, H, N, F, and O (Table 4). Comparison of the experimental percent composition values for the 1:1 and 1:2 co-crystals with the theoretical values indicated that the sample more closely matched the 1:2 co-crystal. This result is consistent with other characterization data.
[0209] Table 4: Elemental analysis of 4a / L-proline form B
[0210]
[0211] Figure 4The dynamic vapor sorption (DVS) isotherm of Form B is shown in . A weight gain of 2.3% by weight was noted between 5% and 95% RH, with most of the adsorption occurring above 50% RH. All of this weight was lost upon desorption and a small hysteresis was noted. The vapor sorption kinetic equilibrium timed out in the adsorption step between 85% and 95% RH, indicating that the co-crystal could potentially absorb more water than measured if longer equilibrium times were allowed. Analysis of the post-DVS material by XRPD showed no significant change in form.
[0212] The IR and Raman spectra of Form B were obtained and analyzed at Figure 5 and Figure 6 Shown in.
[0213] Example 5: Single Crystal X-ray Structure Determination of 4a / L-Proline Form B
[0214] Data Collection
[0215] 4a / L-proline form B (C) with a size of approximately 0.70×0.45×0.30 mm 34 H 48 F3O 10 [C 24 H 30 Colorless plates of FNO6,2(C5H9NO2)]) were mounted on nylon rings in random orientation. The diffractometer was equipped with confocal optics using Cu Kα radiation (λ = ) performed preliminary inspection and data collection. Refinement was performed using SHELX2013 (Sheldrick, GM Acta Cryst., 2008, A64, 112).
[0216] The cell constants and orientation matrices for data collection were obtained from least squares refinement using a set angle of 21646 reflections in the range of 4°<θ<68°. The refinement mosaic from DENZO / SCALEPACK was 0.44°, indicating good crystal quality (Otwinowski, Z.; Minor, W. Methods Enzymol. 1997, 276, 307). The space group was determined by the program XPREP (Bruker, XPREP in SHELXTL v.6.12., Bruker AXS Inc., Madison, WI, USA, 2002). Systematic presence according to the following conditions: 0k0 k=2n, and the space group was determined to be P21 (no.4) according to subsequent least squares refinement.
[0217] Data were collected at room temperature to a maximum diffraction angle (2θ) of 135.73°.
[0218] Data reduction
[0219] The frames were integrated using HKL3000 (Otwinowski (1997)). A total of 21646 reflections were collected, of which 5936 were unique. Lorentz and polarization corrections were applied to the data. The linear absorption coefficient for Cu Kα radiation is 0.833 mm -1 . An empirical absorption correction using SCALEPACK (Otwinowski (1997)) was applied. The transmission coefficient ranged from 0.128 to 0.779. A quadratic extinction correction (Sheldrick (2008)) was applied. The final coefficient refined by the least squares method was 0.0157 (11) (in absolute units). The equivalent reflection intensities were averaged. The consistency factor based on the intensity average was 4.1%.
[0220] Structure elucidation and refinement
[0221] The structure was solved by direct methods using SHELXT (Sheldrick (2008)). The remaining atoms were located in a subsequent difference Fourier synthesis. Hydrogen atoms were included in the refinement but were constrained to straddle the atoms to which they were bonded. The structure was refined with full-matrix least squares by minimizing the function:
[0222] ∑w(|F o | 2 -|F c | 2 ) 2
[0223] The weight w is defined as 1 / [σ 2 (F o 2)+(00640P) 2 +(0.5095P)], where P = (F o 2 +2F c 2 ) / 3.
[0224] The scattering factors are taken from the International Tables for Crystallography, Vol. C, Kluwer Academic Publishers: Dordrecht, The Netherlands, 1992, Tables 4.2.6.8 and 6.1.1.4. Of the 5936 reflections used in the refinement, only F o 2 >2σ(F o2 ) were used to calculate the fit residual R. A total of 5601 reflections were used in the calculations. The final cycle of refinement contained 490 variable parameters and converged with the following unweighted and weighted consistency factors (maximum parameter shift < 0.01 times its estimated standard deviation):
[0225] R=∑|F o -F c | / ∑F o =0.0422
[0226]
[0227] The observed standard deviation per unit weight (goodness of fit) is 1.062. The height of the highest peak in the final difference Fourier is The height of the smallest negative peak is
[0228] Calculated X-ray powder diffraction (XRPD) pattern
[0229] A calculated XRPD pattern for Cu radiation was generated using Mercury (Macrae, CF Edgington, PR McCabe, P. Pidcock, E. Shields, GP Taylor, R. Towler M. and Van de Streek, J.; J. Appl. Cryst., 2006, 39, 453-457) and the atomic coordinates, space group and unit cell parameters from the single crystal structure.
[0230] Atomic displacement ellipsoids and packing diagrams
[0231] Atomic displacement ellipsoid plots were prepared using Mercury (Macrae (2006)). Atoms are represented by anisotropic thermal ellipsoids with a probability of 50%. Packing plots and additional plots were generated using Mercury (Macrae (2006)). Hydrogen bonds are represented as dashed lines. Evaluation of chiral centers was performed using PLATON (Spek, AL PLATON. Molecular Graphics Program. Utrecht University, Utrecht, The Netherlands, 2008; Spek, AL, J. Appl. Cryst. 2003, 36, 7). Absolute configuration was evaluated using the canonical rules for molecular chirality (Cahn, R.S.; Ingold, C.; Prelog, V. Angew. Chem. Intern. Ed. Eng., 1966, 5, 385; Prelog, V., Helmchen, G. Angew. Chem. Intern. Ed. Eng., 1982, 21, 567).
[0232] result
[0233] The monoclinic unit cell parameters and calculated volume are: β=109.309(2)°(α=γ=90°), The formula weight of the asymmetric unit in the Form B crystal structure is 677.75 g mol -1 , Z = 2, the calculated density is 1.313 g cm -3 The space group determined was P21 (no. 4). A summary of the crystal data and crystallographic data collection parameters is provided in Table 5.
[0234] Table 5 Crystallographic data and data collection parameters for 4a / L-proline Form B
[0235]
[0236]
[0237] a Otwinowski, Z.; Minor, W. Methods Enzymol. 1997, 276, 307.
[0238] b Flack,HD Acta Cryst.,1983A39,876.
[0239] cHooft,RWW,Straver,LH,and Spek,ALJAppl.Cryst.,2008,41,96-103.
[0240] The space group and unit cell parameters were consistent with those obtained from XRPD analysis of Form B (see Table 3 above).
[0241] The quality of the obtained structure was high, as indicated by the fit residual R of 0.0422 (4.22%). R values of 0.02 to 0.06 were cited for the most reliably determined structures (Glusker, Jenny Pickworth; Trueblood, Kenneth N. Crystal Structure Analysis: A Primer, 2 nd ed.; Oxford University press: New York, 1985; p. 87).
[0242] Figure 7 Atomic displacement ellipsoid plots of Form B are shown in . The molecules observed in the asymmetric unit of the single crystal structure are consistent with the proposed molecular structure of 4a. Figure 7 The asymmetric unit shown in Figure 1 contains one 4a molecule and two L-proline molecules, consistent with a 1:2 4a:L-proline stoichiometry. Two protons were independently localized and refined on the two proline nitrogen atoms, indicating zwitterions. The two L-proline molecules were disordered on two positions, refined to 82 / 18% and 71 / 29% occupancy.
[0243] The absolute structure can be determined by analyzing the scattering of anomalous X-rays by the crystal. The refinement parameter x, called the Flack parameter (Flack, HD; Bernardinelli, G., Acta Cryst. 1999, A55, 908; Flack, HD; Bernardinelli, G., J. Appl. Cryst. 2000, 33, 1143; Flack, HD Acta Cryst. 1983, A39, 876; Parsons, S., Flack, HD, Wagner, T., Acta Cryst. 2013, B69, 249-259) encodes the relative abundance of the two components in the inversion twin. The structure contains the fraction 1-x of the model in the refinement and its inversion x. Assuming a low standard uncertainty is obtained, the Flack parameter should be close to 0 if the resolved structure is correct, and the Flack parameter should be close to 1 if the inverse model is correct. Figure 7The measured Flack parameter for the Form B structure shown in is -0.02 with a standard uncertainty of 0.11, which indicates that the back resolution is poor and therefore the Flack parameter cannot be interpreted. The error in the standard uncertainty prevents an assignment based solely on the Flack factor.
[0244] Refinement of the Flack parameter (x) does not lead to quantitative statements about the absolute structural assignment. However, applying Bayesian statistics to the Bijvoet method can provide a range of probabilities for different hypotheses of the absolute structure (Hooft, RWW, Straver, LH, and Spek, ALJ Appl. Cryst., 2008, 41, 96-103; Bijvoet, JM; Peerdeman, AF; van Bommel AJ Nature 1951, 168, 271). In addition to the probability that the absolute structure is correct, incorrect, or racemic twinned, the analysis also provides the Flack equivalent (Hooft) parameter. For the current data set, the Flack equivalent (Hooft) parameter was determined to be -0.02 (5), with a probability of 1.000 for the structure to be correct and a probability of 0.9×10 -91 , and the probability that the material is a racemic twin is 0.2×10 -24 .therefore, Figure 7 The absolute configuration of the model in is correct. The structure contains four chiral centers located at C7, C9, C11, and C12 on 4a ( Figure 7 ), which are bonded in R, R, S and R configurations, respectively, and one chiral center on each proline molecule at both C26 and C31 is bonded in S configuration.
[0245] Figure 8 The calculated XRPD pattern of Form B generated from the single crystal structure is shown. The previously indexed experimental XRPD pattern of Form B (Example 4) is shown above and is compared with the calculated XRPD Figure 1 To Fig. 9 ).
[0246] Example 6: Preparation and Characterization of 4a / L-Proline Form C
[0247] Equimolar amounts of amorphous 4a and L-proline (1:1) were slurried and then stirred in acetone at room temperature for 3 days. The slurry was filtered to collect Form C as a white solid.
[0248] Form C was also prepared by dissolving equimolar amounts of amorphous 4a and L-proline in EtOH. Acetone was then introduced into the solution by vapor diffusion (VD) to precipitate Form C.
[0249] The data indicate that Form C consists of a 1:1 co-crystal with 1 mole of acetone present in the crystal lattice, although acetone does not participate in hydrogen bonding. Single crystal data provide confirmation of the chemical and solid phase composition.
[0250] The XRPD pattern of Form C was successfully indexed ( Fig.10 ) and the observed peaks are shown in Table 6.
[0251] Table 6: Peaks observed for 4a / L-proline Form C
[0252]
[0253]
[0254] The unit cell parameters from the XRPD index are shown in Table 7 below:
[0255] Table 7: Unit cell parameters of 4a / L-proline form C
[0256]
[0257] The TGA thermogram of Form C shows a stepwise weight loss, consistent with the finding that this material consists of an acetone solvate ( Fig.11 ). The acetone appears to volatilize in two separate steps. In the first step, a 2.6% weight loss is observed between about 60°C and 150°C. Assuming the volatile is acetone, 2.6% corresponds to 0.26 moles by weight (or about 1 / 4 of the total acetone per single crystal structure). The second weight loss step between 150°C and 220°C corresponds to a 6.7% weight loss, or 0.70 mol if acetone is assumed to be the only volatile.
[0258] Example 7: Single Crystal X-ray Structure Determination of 4a / L-Proline Form C
[0259] The size of C is about 0.19×0.18×0.10mm. 32 H 45 FN209[C 24 H 30 FNO6, C5H9NO2, C3H6O] colorless plates were mounted on the fibers in random orientation. The diffractometer was equipped with confocal optics using Cu Kα radiation. Preliminary inspection and data collection were performed. Refinement was performed using SHELX2013 (Sheldrick (2008)).
[0260] The cell constants and orientation matrix for data collection were obtained from least squares refinement using a set angle of 12615 reflections in the range 4° <θ < 59°. The refinement mosaic from DENZO / SCALEPACK was 0.25°, indicating good crystal quality (Otwinowski (1997)). The space group was determined by the program XPREP (Bruker (2002)). Based on the systematic presence of the following conditions: 0k0k = 2n, and subsequent least squares refinement, the space group was determined to be P21 (no. 4).
[0261] Data were collected at room temperature to a maximum diffraction angle (2θ) of 117.84°.
[0262] The frames were integrated using HKL3000 (Bruker (2002)). A total of 12615 reflections were collected, of which 4368 were unique. Lorentz and polarization corrections were applied to the data. The linear absorption coefficient for Cu Kα radiation is 0.788 mm -1 An empirical absorption correction using SCALEPACK (Bruker (2002)) was applied. The transmission coefficient ranged from 0.060 to 0.924. A quadratic extinction correction (Sheldrick (2008)) was applied. The final coefficient refined by the least squares method was 0.0049 (7) (in absolute units). The equivalent reflection intensities were averaged. The consistency factor based on the intensity average was 4.8%.
[0263] The structure was solved and refined in a manner similar to Example 5 above. Of the 4368 reflections used in the refinement, only F o 2 >2σ(F o 2 ) were used to calculate the fit residual R. A total of 3518 reflections were used in the calculation. The final cycle of refinement contained 417 variable parameters and converged with the following unweighted and weighted consistency factors (maximum parameter shift < 0.01 times the standard deviation of its estimate):
[0264] R=∑|F o -F c | / ∑F o =0.0535
[0265]
[0266] The observed standard deviation per unit weight (goodness of fit) is 1.078. The height of the highest peak in the final difference Fourier transform is The height of the smallest negative peak is
[0267] Calculated XRPD patterns and atomic displacement ellipsoidal plots were generated according to the procedure in Example 5.
[0268] The monoclinic unit cell parameters and calculated volume are: β=107.937(4)°(α=γ=90°), The formula weight of the asymmetric unit in the Form C crystal structure is 620.70 g mol -1 , Z = 2, the calculated density is 1.252 g cm -3 The space group was determined to be P21 (no. 4). A summary of the crystal data and crystallographic data collection parameters is provided in Table 8. The space group and unit cell parameters were consistent with those previously obtained by XRPD indexing (Example 6).
[0269] Table 8 Crystallographic data and data collection parameters for 4a / L-proline Form C
[0270]
[0271]
[0272] a Otwinowski (1997).
[0273] b Flack (1983).
[0274] c Hooft (2008).
[0275] Fig.12 Atomic displacement ellipsoid plots of Form C are shown in . The molecules observed in the asymmetric unit of the single crystal structure are consistent with the proposed molecular structure of 4a / L-proline. Fig.12 The asymmetric unit shown in contains a molecule of 4a, a molecule of L-proline, and a molecule of acetone. The two protons are independently localized and refined on the proline nitrogen atom, indicating a zwitterion.
[0276] Fig.13 The calculated XRPD pattern of Form C generated from a single crystal structure is shown. As described above, Fig.10 The experimental XRPD pattern of the bulk material from which the crystals were obtained is shown in . All peaks in the experimental pattern are represented by the calculated XRPD pattern, indicating that the bulk material is likely a single phase. Differences in intensity between the calculated and experimental powder diffraction patterns are generally attributed to a preferred orientation. The preferred orientation is the tendency of the crystals to arrange themselves in a certain degree of order. This preferred orientation of the sample can significantly affect the peak intensity in the experimental powder diffraction pattern, but does not affect the peak position.
[0277] For the current data set, the Flack equivalence (Hooft) parameter was determined as described in Example 5 and was determined to be 0.09 (9), with a probability of 1.000 that the structure was correct and a probability of 0.4 × 10 -21 and the probability that the material is a racemic twin is 0.4×10 -4 .
[0278] therefore, Fig.12 The absolute configuration of the model in is probably correct. This structure contains four chiral centers at C7, C9, C11, and C12 on 4a ( Fig.12 ), which are bonded in R, R, S, R configurations respectively; and one chiral center at C26 on proline is bonded in S configuration.
[0279] Example 8: Preparation and Characterization of 4a / L-Proline Form D
[0280] Equimolar amounts of amorphous 4a and L-proline were mixed in acetonitrile to give a thin suspension, which was then heated to about 85° C. The suspension was cooled to about 71° C., seeded with a small amount of the material prepared in Example 1, and maintained at about 71° C. for about 15 minutes. The suspension was then allowed to slowly cool to room temperature and then stirred for three days. The resulting white suspension was filtered to produce Form D, which was then dried.
[0281] Form D was also prepared by combining equimolar amounts of amorphous 4a and L-proline in EtOH, heating to about 82°C and maintaining at that temperature for about 15 minutes, cooling to about 76°C, seeding with a small amount of the material prepared in Example 1, slowly cooling to temperature, and stirring for three days. The resulting off-white slurry was filtered, and the collected amount of Form D was dried under vacuum at about 48°C.
[0282] Form D consists of anhydrous / unsolvated 1:2 4a / L-proline cocrystals. The XRPD pattern of Form D has been successfully indexed, indicating that the material consists primarily or exclusively of a single crystalline phase ( Fig.14 , Table 9). The unit cell volumes obtained from the indexed solutions (Table 10) are consistent with the anhydrous 1:2 4a / L-proline co-crystals.
[0283] Table 9: Peaks observed for 4a / L-proline Form D
[0284]
[0285]
[0286] Table 10: Unit cell parameters of 4a / L-proline form D
[0287]
[0288] Form D was characterized by thermal techniques, proton NMR, HPLC and DVS. Fig.15 An overlay of the DSC and TGA thermograms of dried Form D is shown in FIG. The inapparent weight loss up to 185° C. by TGA and the lack of an extensive desolvation endotherm by DSC are consistent with anhydrous / nonsolvated material. A small extensive endotherm is observed at 132° C. (peak maximum). The sharp endotherm starting at 211° C. corresponds to a sharp stepwise weight loss of 26% by weight in the TGA thermogram, which may correspond to simultaneous melting of the co-crystal and volatilization of L-proline.
[0289] Proton NMR data indicated a 1:2 stoichiometry of 4a / L-proline. 0.2% by weight of residual EtOH was detected. The purity of 4a in the sample was 99.6% by HPLC.
[0290] Fig.16 The DVS isotherm for Form D is shown in Figure 2. The material exhibits significant hygroscopicity, especially above RH 55%, with a weight gain of 4.7% by weight noted between 5% and 95% RH. All of this weight is lost upon desorption, with a small hysteresis observed. Notably, the vapor sorption kinetic equilibrium is timed out during the adsorption step between 85% and 95% RH, suggesting that the co-crystal could potentially absorb more water than measured if longer equilibration times were allowed.
[0291] Example 9: Preparation and Characterization of 4a / L-Proline Form G
[0292] Amorphous 4a, pyrazine, and L-proline were combined at a molar ratio of 1:20:1, respectively, by first dissolving pyrazine in methyl ethyl ketone and MeOH (90:10, v / v). The pyrazine solution was added to the 4a and L-proline mixture and stirred at room temperature for two days to give an opaque white suspension. Form G was isolated by vacuum filtration of the suspension.
[0293] Form G consists of 4a / L-proline co-crystals solvated by MEK. Form G exhibits a unique crystal pattern ( Fig.17 ).
[0294] Table 11: Peaks observed for 4a / L-proline Form G
[0295]
[0296]
[0297] The unit cell volumes obtained from the indexed XRPD pattern (Table 12) are consistent with a 1:1 4a / L-proline cocrystal in which at most 1 mole of MEK or pyrazine is present (the volumes of the MEK and pyrazine molecules are comparable and cannot be distinguished by XRPD indexing). The unit cell parameters (Table 12) also indicate that Form G is isostructural with Forms B and C. Form G was confirmed by proton NMR to contain 4a, L-proline, MEK, and minor residual pyrazine in a molar ratio of approximately 1:1.2:0.6:0.1.
[0298] Table 12: Unit cell parameters of 4a / L-proline form G
[0299]
[0300]
[0301] Single crystal analysis of Form B and Form C suggests that these forms are isostructural, with 4a and L-proline forming channels that accommodate additional L-proline for Form B and acetone for Form C. Neither the L-proline nor the acetone molecules in each channel form hydrogen bonds with the molecules that make up the channel. As described above, the space group and other unit cell parameters obtained for Form G suggest that it is isostructural with Forms B and C. Although other explanations are possible, given what is known about the molecular packing of these forms and the non-stoichiometric equivalents of L-proline and MEK in Form G as determined by proton NMR, the channels in Form G likely accommodate both L-proline and MEK in a non-stoichiometric (and potentially variable) ratio due to the ease of exchange that occurs due to the lack of hydrogen bonding within the channels.
[0302] Example 10: Purification of 4a by co-crystal formation
[0303] A. Purification with L-proline
[0304] Co-crystallization of 4 according to the above procedure leads to Form B and Form D, and thereby very effectively reduces the amount of the β-anomer 4b. A typical batch of amorphous 4 as determined by HPLC consists of 93.2% / 6.3% 4a / 4b. After the co-crystal formation step in a typical experiment, the level of 4b is reduced from 6.3% to 2.4% (HPLC). The resulting 4a / L-proline co-crystals are recrystallized by mixing them with MeOH (2 volumes) and heating the mixture to reflux for 3 hours. The mixture is cooled to 0±3°C within 2.5 hours and then stirred overnight. The resulting solid is collected by filtration. After recrystallization, the amount of 4b is further reduced to 1.2%, and the purity of 4a is increased to 98.7% (HPLC).
[0305] B. Purification with D-proline
[0306] The amount of amorphous compound 4 alone as determined by HPLC contained 89.3% of 4a and 10.1% of 4b. Compound 4 (300 mg, 0.670 mmol) and D-proline (77.3 mg, 0.671 mmol) in EtOH (2.4 mL) were heated in an oil bath at 90°C. After reflux for 15 minutes, the resulting solution was cooled to room temperature in a vial and kept for 24 hours with the vial cap removed to allow EtOH to evaporate slowly at room temperature. The precipitated solid was collected by filtration and dried in air to give 4a / D-proline co-crystals. The co-crystals as determined by HPLC contained 97.6% of 4a and 2.1% of 4b (150 mg as a white solid, 40% yield). 1 H NMR analysis showed that the molar ratio of 4a to D-proline was 1:1.
[0307] Example 11: Preparation and characterization of 4a / D-proline cocrystals
[0308] A mixture of compound 4a (100 mg, 0.223 mmol) and D-proline (25.8 mg, 0.224 mmol) in EtOH (0.8 mL) was heated in an oil bath at 90° C. After reflux for 15 minutes, the solution was cooled to room temperature and kept in a capped vial at room temperature for 24 hours. The vial cap was then removed to allow the EtOH to evaporate slowly at room temperature. After 24 hours, the precipitated solid was collected by filtration and then dried in air to give 4a / D-proline co-crystals (74 mg, 59% yield) as white solids with 99+% purity (HPLC). 1 H NMR analysis showed that the co-crystal contained compound 4a and D-proline in a 1 / 1 ratio.
[0309] The 4a / D-proline co-crystals were characterized by XRPD, DSC, TGA, and DVS. The XRPD pattern of the 4a / D-proline co-crystals was successfully indexed, indicating that the material was mainly or only composed of a single crystalline phase ( Fig.18 , Table 13).
[0310] Table 13: Peaks observed for 4a / D-proline
[0311]
[0312]
[0313]
[0314] Fig.19The DSC / TGA overlay of this material is shown in . The TGA thermogram of the 4a / D-proline cocrystal exhibits two distinct weight loss steps, the first occurring between about 100°C and 150 to 160°C (7.0% weight loss), and the second between 150°C and 230°C (20.0% weight loss). A broad endotherm was observed by DSC with a peak maximum at 130°C, which is coordinated with the first TGA weight loss step, which may be attributed to the loss of bound solvent / water. Overlapping endothermic events were observed above about 170°C, likely due to simultaneous melting / volatilization of the D-proline component of the cocrystal. The sharp drop in the TGA thermogram above about 250°C may correspond to decomposition.
[0315] Fig. 20 The DVS isotherm of the D-proline co-crystal is shown in . After adsorption, the co-crystal gained 26% by weight between 5% and 95% RH, with the majority of the weight gain occurring between 85% and 95% RH. The kinetic equilibrium timed out during this step, indicating that the co-crystal could potentially absorb more water than measured if longer equilibration times were allowed. After desorption, the co-crystal showed a relatively steady weight loss between 95% and 5% RH, and lost more weight than gained during adsorption (29% by weight), indicating that the material may contain solvent / water at the start of the analysis. Notably, the post-DVS sample of the D-proline co-crystal was observed to stick to the pan and could not be recovered, indicating partial deliquescence during the experiment.
[0316] Example 12: Comparison of administration of 4a / L-proline material A and amorphous 4a to mice
[0317] This example evaluates the systemic exposure to 4a following oral administration of a suspension formulation of Material A as prepared in Example 1 compared to a suspension formulation of amorphous 4a in male C57BL / 6 mice.
[0318] Amorphous 4a or material A (taking into account the presence of proline on a weight basis) was formulated in 0.5% CMC with 5% DMSO and administered to 35 male C57BL / 6 mice at 1000 mg / kg by oral gavage using a dosing volume of 15 mL / kg. Blood samples for plasma separation were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours after dosing, as summarized in Table 14 below, using separate groups of mice for each time point (n=5 / group / time point). Plasma samples were analyzed by LC / MS / MS methods as described below for the concentration of 4a.
[0319] Table 14: Summary of Mouse Studies
[0320]
[0321] Reagents and Supplies: All reagents and supplies were of high quality and LC / MS grade where appropriate and were obtained from standard commercial suppliers.
[0322] Plasma sample preparation: 4a was extracted from K3EDTA-fortified plasma samples using a protein precipitation method. In a well of a polypropylene microplate (96-well), 20 μL of a 2.5-ng / mL D3-4a (internal standard, IS) solution prepared in acetonitrile / H2O (1:1) was added, followed by 20 μL of plasma sample. The plate was sealed with sealing tape (Phenomenex, AH0-7362) and gently mixed with a vortex mixer for 1 minute. The solution was pipetted into a well of a polypropylene plate (96-well, 2 mL, Phenomenex, AH0-7194) containing 500 μL of methanol. The plate was sealed and vortexed for 5 minutes, followed by centrifugation at 3000×g for 3 minutes at room temperature. A 300 μL aliquot of the supernatant was transferred to a new well containing 300 μL of deionized water. After gentle mixing, the plate was sealed and placed in an LC autosampler maintained at 12°C, and a 10 μL aliquot was injected into the LC / MS / MS system for quantitative analysis of 4a.
[0323] Chromatographic and mass spectrometric conditions: Liquid chromatography separation of 4a was achieved by a reverse phase analytical column with a mobile phase solution containing H2O, acetonitrile and formic acid. Chromatographic analytes were detected by a Waters Xevo TQ-S triple quadrupole mass spectrometer operated in multiple-reaction-monitoring (MRM) mode. The chromatographic peak areas of quality control samples, calibration standards and research samples were integrated using MassLynx software V4.1 (Waters Corp.).
[0324] Pharmacokinetic analysis: using WinNonlin TM Pharmacokinetic parameter estimates were obtained from noncompartmental analysis of the mean 4a plasma concentration-time data for each dose group using Pharsight software version 6.3 (Pharsight Corp., Cary, NC). The area under the plasma concentration-time curve (AUC) from time zero to the time (t) of the last measurable concentration at 4a was determined using the linear logarithmic trapezoidal rule. (0至t) The time of the last measurable concentration was defined as the time when the 4a concentration in the majority of animals in each dose group was below the limit of quantitation (BLQ).
[0325] Results: Mean (±SD) 4a plasma concentration-time data following single oral gavage administration of Material A and amorphous 4a are shown in Table 15 below and are presented in Table 16. Fig.21 The estimated pharmacokinetic parameters of 4a are shown in Table 16.
[0326] Table 15: Mean (±SD) plasma concentrations of 4a in mice after administration of a single oral dose of Material A and amorphous 4a
[0327]
[0328] a All samples in the group were BLQ.
[0329] Table 16: Estimated plasma pharmacokinetic parameters following a single oral administration to mice
[0330]
[0331] Example 13: Comparison of administration of 4a / L-proline material A and amorphous 4a to monkeys
[0332] This example evaluates the systemic exposure of Material A and Amorphous 4a formulations as prepared in Example 1 in male cynomolgus monkeys following a single oral gavage administration at 30 mg / kg using 0.5% carboxymethyl cellulose (CMC) in sterile water as a vehicle (5 mL / kg) or a single oral gavage administration at 50 mg (regardless of body weight) in loose-fill capsules, respectively, as summarized in Table 17 below.
[0333] Table 17: Summary of Monkey Studies
[0334]
[0335] a The dose administered does not take into account body weight
[0336] b NA, not applicable
[0337] The administration of material A took into account the presence of proline on a weight basis. Blood samples were collected from each monkey for plasma separation at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after administration. Plasma samples were analyzed for 4a concentration by LC / MS / MS method and pharmacokinetic analysis was performed as described in Example 12 above.
[0338] Results: Mean (±SD) plasma concentrations after a single oral gavage (30 mg / kg, 5 mL / kg) or capsule administration (50 mg) are shown in Table 18 below and Fig. 22 The estimated pharmacokinetic parameters are shown in Table 19.
[0339] Table 18: Mean (±SD) 4a plasma concentrations in monkeys after oral administration of Material A or amorphous 4a as a suspension or capsule
[0340]
[0341] a Two of the three values at the intermediate time points (ie, with quantifiable values between the two time points) were below the limit of quantitation (BLQ) and contained within the mean value of 1 / 2 the lower limit of quantitation (LLOQ) (ie, 0.200 ng / mL).
[0342] b All values at intermediate time points (i.e., with quantifiable values between two time points) are BLQ and are reported as 1 / 2 of the LLOQ (i.e., 0.200 ng / mL)
[0343] c One of the three values was the BLQ and was assigned a value of 1 / 2 of the LLOQ (i.e., 0.200 ng / mL) to calculate the mean and standard deviation.
[0344] d The average is reported as BLQ because 2 of 3 samples were BLQ
[0345] e All values are BLQ
[0346] Table 19: Mean (±SD) pharmacokinetic data in monkeys following administration of 4a suspension or capsules by oral gavage
[0347]
[0348] a Data are expressed as median
[0349] Both capsule formulations (but not the oral suspension formulation) produced 4a plasma concentrations below or close to the lower limit of quantitation (i.e., 0.400 ng / mL) at 4 and 8 hours after administration, but showed a secondary exposure peak at 24 hours, with mean (±SD) 4a concentrations of 12.5±11.0 and 6.11±9.23 ng / mL for Material A and amorphous 4a formulations, respectively.
[0350] The following content corresponds to the original claims in the parent application and is now incorporated herein as part of the specification:
[0351] 1. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:2), characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.76, 16.86, 19.00 and 21.05° 2θ ± 0.20° 2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
[0352] 2. The co-crystal according to item 1, wherein the X-ray powder diffraction pattern further comprises peaks at 12.14, 17.51, 18.89 and 19.41° 2θ±0.20° 2θ.
[0353] 3. A co-crystal according to item 1 or 2, wherein the X-ray powder diffraction pattern is substantially as follows Figure 1 shown.
[0354] 4. The co-crystal of any one of items 1 to 3, characterised by a differential scanning calorimetry (DSC) thermogram comprising an exotherm at about 211°C.
[0355] 5. The co-crystal according to claim 4, wherein the DSC thermogram is substantially as follows Figure 2 shown.
[0356] 6. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:2), characterized by an X-ray powder diffraction pattern comprising the following peaks: 9.20, 16.19, 18.45 and 24.51 °2θ±0.20 °2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
[0357] 7. The co-crystal of item 6, wherein the X-ray powder diffraction pattern further comprises peaks at 11.83, 17.16, 20.15 and 25.34° 2θ ± 0.2° 2θ.
[0358] 8. A co-crystal according to item 6 or 7, wherein the X-ray powder diffraction pattern is substantially as follows Fig.14 shown.
[0359] 9. The co-crystal of any one of items 6 to 8, characterised by a differential scanning calorimetry (DSC) thermogram comprising an endotherm with an onset temperature of about 211.2°C.
[0360] 10. The co-crystal of claim 9, wherein the DSC thermogram is substantially as follows Fig.15 shown.
[0361] 11. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline acetone solvate (1:1:1), characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.64, 17.53, 18.91 and 21.33 °2θ±0.20 °2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
[0362] 12. The co-crystal of item 11, wherein the X-ray powder diffraction pattern further comprises peaks at 12.10, 15.14, 18.26 and 19.56° 2θ ± 0.2° 2θ.
[0363] 13. The co-crystal according to item 11 or 12, wherein the X-ray powder diffraction pattern is substantially as follows Fig.10 shown.
[0364] 14. The co-crystal of any one of items 11 to 13, characterized by a thermogravimetric analysis (TGA) thermogram comprising a weight loss step completed at about 150°C to about 220°C.
[0365] 15. The co-crystal of claim 14, wherein the TGA thermogram is substantially as follows Fig.11 shown.
[0366] 16. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide, L-proline, methyl ethyl ketone, and pyrazine in a molar ratio of about 1:1.2:0.6:0.1, characterized by an X-ray powder diffraction pattern comprising peaks at 10.42, 14.62, 19.28, and 21.14° 2θ ± 0.20° 2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
[0367] 17. The co-crystal of claim 16, wherein the X-ray powder diffraction pattern further comprises peaks at 11.85, 14.93, 17.40 and 19.28° 2θ ± 0.2° 2θ.
[0368] 18. The co-crystal according to item 16 or 17, wherein the X-ray powder diffraction pattern is substantially as follows Fig.17 shown.
[0369] 19. The co-crystal according to any one of items 16 to 18, characterized by the following unit cell dimensions: α=90°, β=108.56°, and γ=90°.
[0370] 20. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and D-proline (1:1), characterized by an X-ray powder diffraction pattern comprising the following peaks: 11.77, 14.52, 19.54 and 21.23° 2θ ± 0.20° 2θ, as measured using a wavelength of Cu-K α1 The radiation is determined on a diffractometer.
[0371] 21. The co-crystal of claim 20, wherein the X-ray powder diffraction pattern further comprises peaks at 8.45, 13.18, 16.95 and 19.12° 2θ±0.2° 2θ.
[0372] 22. The co-crystal according to item 20 or 21, wherein the X-ray powder diffraction pattern is substantially as follows Fig.18 shown.
[0373] 23. The co-crystal of any one of items 20 to 22, characterised by a differential scanning calorimetry (DSC) thermogram comprising an endotherm at about 130°C.
[0374] 24. The co-crystal of claim 23, wherein the DSC thermogram is substantially as follows Fig.19 shown.
[0375] 25. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline (1:1), characterized by an X-ray powder diffraction pattern comprising the following peaks: 8.52, 16.33, 19.50 and 21.22 °2θ±0.20 °2θ, as measured using a wavelength of Cu-K α1 The radiation is determined on a diffractometer.
[0376] 26. The co-crystal of claim 25, wherein the X-ray powder diffraction pattern further comprises peaks at 9.19, 13.22, 14.75 and 17.57° 2θ ± 0.2° 2θ.
[0377] 27. The co-crystal according to item 25 or 26, wherein the X-ray powder diffraction pattern is substantially as follows Fig.23 shown.
[0378] 28. The co-crystal according to any one of items 25 to 27, characterized by the following unit cell dimensions: α=90°, β=90°, and γ=90°.
[0379] 29. The co-crystal of any one of items 25 to 27, characterised by a differential scanning calorimetry (DSC) thermogram comprising an endotherm at about 145°C.
[0380] 30. The co-crystal of claim 29, wherein the DSC thermogram is substantially as follows Fig.24 shown.
[0381] 31. A pharmaceutical composition comprising the co-crystal according to any one of items 1 to 30 and a pharmaceutically acceptable solid carrier.
[0382] 32. A method for inhibiting heat shock protein 90 (Hsp90) in a subject, comprising administering to the subject a therapeutically effective amount of a co-crystal according to any one of items 1 to 30.
[0383] 33. A method for treating or preventing a neurodegenerative disorder in a subject suffering from the neurodegenerative disorder, comprising administering to the subject a therapeutically effective amount of a co-crystal according to any one of items 1 to 30.
[0384] 34. A method according to claim 33, wherein the neurodegenerative disorder is diabetic peripheral neuropathy.
[0385] 35. A method for preventing the development or reducing the likelihood of developing diabetic peripheral neuropathy in a subject, comprising administering to the subject a therapeutically effective amount of a co-crystal according to any one of items 1 to 30, wherein the subject suffers from type 1 or type 2 diabetes.
[0386] 36. Increasing the activity of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) relative to N-(2-(5-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide (4a) A method for reducing the concentration of 4a in a starting composition comprising 4a and 4b, comprising contacting the starting composition with proline in a solvent, and subjecting the starting composition, proline and solvent to crystallization conditions, thereby producing a co-crystal of 4a and proline, wherein the bulk co-crystal exhibits a higher concentration of 4a than in the starting composition comprising 4a and 4b.
[0387] 37. A method according to claim 36, wherein the proline is L-proline.
[0388] 38. A method according to claim 36, wherein the proline is D-proline.
[0389] 39. The method according to any one of items 36 to 38, wherein the method further comprises heating the starting composition, proline and solvent.
[0390] 40. A method according to any one of items 36 to 39, wherein the concentration of 4a is determined by HPLC.
[0391] 41. A method according to any one of items 36 to 40, wherein the concentration of 4a in the bulk co-crystal of 4a and proline is about 3% to about 20% (w / w) higher than in the starting composition.
[0392] 42. A method according to any one of items 36 to 41, wherein the concentration of 4a in the bulk co-crystal of 4a and proline is about 5% to about 15% (w / w) higher than in the starting composition.
[0393] 43. A method according to any one of items 36 to 42, wherein the concentration of 4a in the bulk co-crystal of 4a and proline is increased by about 5%, about 10% or about 15% (w / w).
[0394] 44. A co-crystal according to any one of items 1 to 30 for use in treating or preventing a neurodegenerative disorder in a subject suffering from the neurodegenerative disorder.
[0395] 45. A co-crystal according to any one of items 1 to 30 for use in preventing the development or reducing the likelihood of developing diabetic peripheral neuropathy in a subject suffering from type 1 or type 2 diabetes.
[0396] 46. Use of a co-crystal according to any one of items 1 to 30 for the preparation of a medicament for treating or preventing a neurodegenerative disorder in a subject suffering from the neurodegenerative disorder.
[0397] 47. Use of a co-crystal according to any one of items 1 to 30 for the preparation of a medicament for preventing the development or reducing the likelihood of developing diabetic peripheral neuropathy in a subject with type 1 or type 2 diabetes.
Claims
1. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline in a molar ratio of 1:2, characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.76, 16.86, 19.00 and 21.05° 2θ ± 0.20° 2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
2. The co-crystal of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at 12.14, 17.51, 18.89 and 19.41° 2θ ± 0.20° 2θ.
3. The co-crystal according to claim 1 or 2, wherein the X-ray powder diffraction pattern is substantially as shown in Figure 1.
4. The co-crystal of claim 1 characterized by a differential scanning calorimetry (DSC) thermogram comprising an exotherm at about 211°C.
5. The co-crystal of claim 4, wherein the DSC thermogram is substantially as shown in Figure 2.
6. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline in a molar ratio of 1:2, characterized by an X-ray powder diffraction pattern comprising the following peaks: 9.20, 16.19, 18.45 and 24.51 °2θ±0.20 °2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
7. The co-crystal of claim 6, wherein the X-ray powder diffraction pattern further comprises peaks at 11.83, 17.16, 20.15 and 25.34° 2θ ± 0.2° 2θ.
8. The co-crystal of claim 6 or 7, wherein the X-ray powder diffraction pattern is substantially as shown in Figure 14.
9. The co-crystal of claim 6, characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm with an onset temperature of about 211.2°C.
10. The co-crystal of claim 9 wherein the DSC thermogram is substantially as shown in Figure 15.
11. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and L-proline acetone solvate in a molar ratio of 1:1:1, characterized by an X-ray powder diffraction pattern comprising the following peaks: 14.64, 17.53, 18.91 and 21.33° 2θ ± 0.20° 2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
12. The co-crystal of claim 11, wherein the X-ray powder diffraction pattern further comprises peaks at 12.10, 15.14, 18.26 and 19.56° 2θ ± 0.2° 2θ.
13. A co-crystal according to claim 11 or 12, wherein the X-ray powder diffraction pattern is substantially as shown in Figure 10.
14. The co-crystal of claim 11 characterized by a thermogravimetric analysis (TGA) thermogram comprising a weight loss step completed at 150°C to 220°C.
15. The co-crystal of claim 14 wherein the TGA thermogram is substantially as shown in Figure 11.
16. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide, L-proline, methyl ethyl ketone, and pyrazine in a molar ratio of about 1:1.2:0.6:0.1, characterized by an X-ray powder diffraction pattern comprising peaks at 10.42, 14.62, 19.28, and 21.14° 2θ ± 0.20° 2θ, as measured using a wavelength of The Cu-Kα radiation was determined on a diffractometer.
17. The co-crystal of claim 16, wherein the X-ray powder diffraction pattern further comprises peaks at 11.85, 14.93, 17.40 and 19.28° 2θ ± 0.2° 2θ.
18. A co-crystal according to claim 16 or 17, wherein the X-ray powder diffraction pattern is substantially as shown in Figure 17.
19. The co-crystal of claim 16, characterized by the following unit cell dimensions: α=90°, β=108.56°, and γ=90°.
20. A co-crystal of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-acetamide and D-proline in a molar ratio of 1:1, characterized by an X-ray powder diffraction pattern comprising the following peaks: 11.77, 14.52, 19.54 and 21.23° 2θ ± 0.20° 2θ, as measured using a wavelength of Cu-K α1 The radiation is determined on a diffractometer.
21. The co-crystal of claim 20, wherein the X-ray powder diffraction pattern further comprises peaks at 8.45, 13.18, 16.95 and 19.12° 2θ ± 0.2° 2θ.
22. The co-crystal of claim 20 or 21 wherein the X-ray powder diffraction pattern is substantially as shown in Figure 18.
23. The co-crystal of claim 20, characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm at about 130°C.
24. The co-crystal of claim 23 wherein the DSC thermogram is substantially as shown in Figure 19.
25. A pharmaceutical composition comprising the co-crystal according to any one of claims 1 to 24 and a pharmaceutically acceptable solid carrier.
26. Use of a co-crystal according to any one of claims 1 to 24 for the preparation of a medicament for inhibiting heat shock protein 90 (Hsp90) in a subject.
27. Use of a co-crystal according to any one of claims 1 to 24 in the preparation of a medicament for treating or preventing a neurodegenerative disorder in a subject suffering from the neurodegenerative disorder.
28. The use according to claim 27, wherein the neurodegenerative disorder is diabetic peripheral neuropathy.
29. Use of a co-crystal according to any one of claims 1 to 24 for the preparation of a medicament for preventing the development or reducing the likelihood of developing diabetic peripheral neuropathy in a subject with type 1 or type 2 diabetes.
Citation Information
Patent Citations
C-terminal HSP90 inhibitors
US9422320B2
